| ‹v—¯•Ä‘åŠw| ˆãŠw•”| S‘ŸEŒŒŠÇ“à‰È| ¬Ž™‰È| ŠO‰È| ‹v—¯•Ä‘åŠw•a‰@|

toiawase
  • §830-0011
  • •Ÿ‰ªŒ§‹v—¯•ÄŽsˆ®’¬67
  • TEL: 0942-35-3800
  • FAX: 0942-31-7707 mailto
‘æ33‰ñ“ú–{‚ŒŒˆ³Šw‰ï‘‰ï
‚Ђç‚ß‚«‚Æ‚«‚ß‚«ƒTƒCƒGƒ“ƒX

Œ¤‹†‹ÆÑ > 2007”N

’˜‘@ ‰p•¶˜_•¶ ˜a•¶˜_•¶ ‘ÛŠw‰ï ‘“àŠw‰ï Ç—á•ñ ‘à Œ°² Œ¤‹†•¬‹à “Á‹–

’˜‘

  1. –ö¬–¾FŠ´õ«S“à–Œ‰Š‚ÌŽ¡—Ãí—ªA ‹¹•”ŠO‰ÈUp to DateA‘æ60‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïPostgraduate CourseƒeƒLƒXƒgF23-30,2007
  2. –ö¬–¾A•Ÿ‰iŽüŽiF‘m–X•Ù‹·óÇAS‘Ÿ•Ù–ŒÇ‚ÌŠO‰È?‘æ‚R”Å?F280-298,2007
  3. –ö¬–¾F‘m–X•Ù’uŠ·p (MVR)AS‘Ÿ•Ù–ŒÇ‚ÌŠO‰È?‘æ‚R”Å?F400-415,2007
  4. ŒÜ\—’—²C¼Î–LŽŸ˜YC{“cŒ›Ž¡Cˆäã’‰•vC–ؒÃŽqŠÄ–óFƒnƒŠƒGƒbƒgƒŒ[ƒ“ƒnƒ“ƒhƒuƒbƒN|ƒWƒ‡ƒ“ƒYEƒzƒvƒLƒ“ƒX•a‰@¬Ž™‰ÈƒŒƒWƒfƒ“ƒgƒ}ƒjƒ…ƒAƒ‹A MEDSiFú@-xviii,2007
  5. {“cŒ›Ž¡–óAKelly KAGajewskiFS‘Ÿ•a.ƒnƒŠƒGƒbƒgƒŒ[ƒ“ƒnƒ“ƒhƒuƒbƒN|ƒWƒ‡ƒ“ƒYEƒzƒvƒLƒ“ƒX•a‰@¬Ž™‰ÈƒŒƒWƒfƒ“ƒgƒ}ƒjƒ…ƒAƒ‹AMEDSiF143-185,2007
  6. {“cŒ›Ž¡–óAJanson RobertsonFŒŒ‰t¶‰»Šw‚Ƒ̉t.ƒnƒŠƒGƒbƒgƒŒ[ƒ“ƒnƒ“ƒhƒuƒbƒN|ƒWƒ‡ƒ“ƒYEƒzƒvƒLƒ“ƒX•a‰@¬Ž™‰ÈƒŒƒWƒfƒ“ƒgƒ}ƒjƒ…ƒAƒ‹AMEDSiF573-585,2007
  7. {“cŒ›Ž¡CH“¡‰ÃŒöC›Œ´—mŽqCΈä³_C¼Î–LŽŸ˜YFŠ¥“®–¬áŽ‚ɑ΂·‚éRŒŒð—Ö@A“ú–{—Õ°F66(2)F355-359,2008
  8. ‘O–ì‘׎÷FEBM‚ÉŠî‚­‘ÙŽ™S‘Ÿ•a‚Ìf’fŽ¡—ÃF‘Ù“àŽ¡—Ẩ”\«‚ÍH EBM¬Ž™Ž¾Š³‚ÌŽ¡—ÃF62-66,2007-2008
  9. ‘O–ì‘׎÷C_“c—mC“¡–ì_Fæ“V«•s®–¬iæ“V«S–[‘e“®Cæ“V«ãŽº«•p”Cæ“V«SŽº•p”Cæ“V«Š®‘S–[ŽºƒuƒƒbƒNj“ú–{—Õ°@zŠÂŠíÇŒóŒQi‘æ‚Q”ÅjF408-412
  10. ‘O–ì‘׎÷CL£²ŽqC_ŒË‘¾˜YF‘ÙŽ™•s®–¬A“ú–{—Õ°@zŠÂŠíÇŒóŒQi‘æ‚Q”ÅjF419-424
  11. ‘O–ì‘׎÷CœA£²ŽqF‘ÙŽ™EV¶Ž™ˆÙí‚ÌŽ¡—ÂƂ»‚Ì—\ŒãA‘ÙŽ™•s®–¬DŽY•wl‰È‚ÌŽÀÛF56:875-881,2007
  12. ‘O–ì‘׎÷FzŠÂŠíŽ¾Š³‚ÌŠî‘b’mŽ¯‚ÆŠÇ—Aæ“V«SŽ¾Š³‚Ìf’f‚ÆŽ¡—ÃANeonatal Care@F20:18-3,2007
  13. Kato H, Takahashi K. Kawasaki's diseaseFEdited by Gene V.Ball, S Louis Bridges, Jr. Vasculitis second editionF373-389,2007-2008
  14. Abe R, Yamagishi S: Novel therapeutic strategy for the treatment of malignant melanoma. Progress in Skin Cancer Research (Horizons in Cancer Research, Volume 30) V.L. Heinz eds., Nova Science, NY, Chapter I: 1-26, 2007
  15. b”ã‹vŽj•ÒWFŠÅŒìŽt‘‰ÆŽŽŒ±@Žã“_Ž•žƒTƒuƒm[ƒgŠî‘bˆãŠw•Ò2007”N“x”ÅA ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐA“Œ‹žF2007
  16. ‰ª@’¼Ž÷A¡ò@•×F‡W.”ì‘åŒ^S‹ØÇ@Œo‰ß‚Æ—\Œã.@V–Ú‚Å‚Ý‚ézŠÂŠí•aƒVƒŠ[ƒY15@S‹ØÇA¼X@º•ÒAƒƒWƒJƒ‹ƒrƒ…[ŽÐA“Œ‹žF164-168,2007.3
  17. ¼‰ªG—mA¡ò@•×FRŽ_‰»–ò‚ÌŒ»ó‚Æ¡Œã‚ÌŠú‘Ò42.ACE‘jŠQ–ò/AT1Žó—e‘ÌhR–ò.@Ž_‰»ƒXƒgƒŒƒX‚ÆSŒŒŠÇ•aA‰¡ŽRŒõGA“¡“c•q˜Y•ÒA“ú–{ˆãŠwo”ÅA “Œ‹žF243-248,2007.4
  18. b”ã‹vŽjFLate-Breaking Basic Session . ISHƒnƒCƒ‰ƒCƒgA]“¡ˆû®A‹e’rŒ’ŽŸ˜YA‘뉺CˆêA’|‰º@²A“¡“c•q˜YA¼‰ª”ŽºAŽO‰YK—Y•ÒAƒƒfƒBƒJƒ‹EƒWƒƒ[ƒiƒ‹ŽÐA“Œ‹žF130-132,2007
  19. ‘«’B@ŽõF“ÁWu‚킪‘‚É‚¨‚¯‚ézŠÂŠí‰uŠwŒ¤‹†‚̃Rƒz[ƒgv“cŽåŠÛŒ¤‹†.@CARDIAC PRACTICEA¡ò@•×•ÒAƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐA“Œ‹žF18(2)F63-66,2007
  20. ‘å“à“c¹’¼A¡ò@•×F‹}«¶S•s‘S.@¡“ú‚̈•ûi‰ü’ù‘æ4”ÅjA‚‹vŽj–›A…“‡@—TŠÄCA‰Y•”»•vA‘å“c@Œ’AŠ™’J’¼”VA“‡“c˜aKA›–쌒‘¾˜YA•’J—Y“ñ•ÒA“ì]“°A“Œ‹žF147-148,2007.4
  21. ‘å“à“c¹’¼A¡ò@•×F–«‚¤‚ÁŒŒ«S•s‘S.@¡“ú‚̈•ûi‰ü’ù‘æ4”ÅjA‚‹vŽj–›A…“‡@—TŠÄCA‰Y•”»•vA‘å“c@Œ’AŠ™’J’¼”VA“‡“c˜aKA›–쌒‘¾˜YA•’J—Y“ñ•ÒA“ì]“°A“Œ‹žF149-150,2007.4
  22. ¼‰ªG—mFŒŒŠÇ“à”ç‹@”\‚Ì‘ª’è–@.@ŒŒŠÇ“à”ç×–E‚ð‚ß‚®‚鎾Š³A“‡“c˜aK•ÒA ^‹»ŒðˆÕˆã‘o”Å•”A“Œ‹žF81-92,2007
  23. Œ´“c°mAb”ã‹vŽjFONE POINT ADVICE ˆâ“`Žqf’f‚ðf—Âɂǂ¤Šˆ‚©‚·‚©. VES‘Ÿ•af—Ãvƒ‰ƒNƒeƒBƒX10@S‹ØÇ‚ðŽ¯‚éEf‚éEŽ¡‚·Aˆé•”ŒõÍA¼è‰v“¿•ÒA •¶Œõ“°A“Œ‹žF37,2007
  24. ŒÃ‰ê‹`‘¥FŠT”O‚Æ’è‹`. ”ì‘åŒ^S‹Øǃnƒ“ƒhƒuƒbƒNAŒÃ‰ê‹`‘¥•ÒA“ú–{ˆãŽ–V•ñŽÐA“Œ‹žF2-7,2007
  25. ŒÃ‰ê‹`‘¥F‰uŠw. ”ì‘åŒ^S‹Øǃnƒ“ƒhƒuƒbƒNAŒÃ‰ê‹`‘¥•ÒA“ú–{ˆãŽ–V•ñŽÐA “Œ‹žF8-12,2007 ‹g“c“TŽqA’r“c‹v—YF‰^“®•‰‰×ŽŽŒ±. ”ì‘åŒ^S‹Øǃnƒ“ƒhƒuƒbƒNAŒÃ‰ê‹`‘¥•ÒA “ú–{ˆãŽ–V•ñŽÐA“Œ‹žF129-138,2007
  26. ŒÃ‰ê‹`‘¥FSë•””ì‘åŒ^S‹ØÇ‚Ì—\Œã‚ÆŽ©‘R—ð. ”ì‘åŒ^S‹Øǃnƒ“ƒhƒuƒbƒNAŒÃ‰ê‹`‘¥•ÒA“ú–{ˆãŽ–V•ñŽÐA“Œ‹žF215-223,2007
  27. ‰Á“¡GŽiA’r“c‹v—YA¡ò@•×FŽ¡—Ãí—ª‚Ì—§‚Ä•û‚ƶŠˆŽw“±. ”ì‘åŒ^S‹Øǃnƒ“ƒhƒuƒbƒNAŒÃ‰ê‹`‘¥•ÒA“ú–{ˆãŽ–V•ñŽÐA“Œ‹žF234-243,2007
  28. ‘ê@Œ’AŒÃ‰ê‹`‘¥FÇðÇ‚Ì—\–h. ”ì‘åŒ^S‹Øǃnƒ“ƒhƒuƒbƒNAŒÃ‰ê‹`‘¥•ÒA“ú–{ˆãŽ–V•ñŽÐA“Œ‹žF254-258,2007

‰p•¶˜_•¶

  1. S.Aoyagi, T.Okazaki, S.Fukunaga, T.UedaFConcomitant Traumatic Aortic Valve and Coronary Artery Injury. Ann Thorac SurgF289-291,2007
  2. E.Tayama, T.Ueda, T.Shojima K.Akasu T.Oda, S.Fukunaga, H.Akashi, S.AoyagiF Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interactive CardioVascular and Thoracic SurgeryF715-719,2007
  3. S.Aoyagi, H.Hori, K.Yoshikawa, K.Arinaga, S.FukunagaFMid-Term Results of Valve Replacement with the ATS Valve : A Seven-Year Follow UP. J. Heart Valve DisF267-274,2007
  4. S.Aoyagi, S.Fukunaga, E.Tayama, T.YoshidaFExtraanatomic Aortic Bypass for Repair of Aortic Coarctation. J Card SurgF436-439,2007
  5. S.Hiromatsu, N.Egawa, Y.Hosokawa, K.Ishihara, H.Yokokura, A.Tanaka, S.AoyagiFA shorter skin incision technique for the repair of infrarenal abdominal aortic aneurysms. Surg TodayF97-102,2007
  6. H.Yokokura, S.Hiromatsu, H.akashi, S.Kato, S.AoyagiFEffects of calcium ahannel blocker azelnidipine on experimentalabdominal aortic aneurysms. Surg TodayF468-473,2007
  7. Suda K, Matsumura M, Nishimura KFEmergency stent implantation into obstructed inferior caval vein in a patient with heterotaxy and anomalous hepatic venous drainage. Pediatrics InternationalF49(2):251-252,2007
  8. Muta H, Ishii M, Iemura M, Suda K, Nakamura Y, Matsuishi TFEffect of revision of Japanese diagnostic criterion for fever in Kawasaki disease on treatment and cardiovascular outcome. Circulation JournalF71(11):1791-1793,2007
  9. Koga M, Kai H, Egami K, Murohara T, Ikeda A, Yasuoka S, Egashira K, Matsuishi T, Kai M, Kataoka Y, Kuwano M, Imaizumi T.FMutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun.F2008 Jan 11;365(2):279-84. Epub 2007 Nov 6
  10. Kasahara M, Kai H, Okamura T, Wada T, Suda K, Imaizumi T, Sagawa kFUsefulness of higt-concentration calcium chloride solution for correction of activated partial thromboplastin time (APTT) in patients with high-hematocrit value. Thrombosis researchF(2007 in press)
  11. Bigras JL, Suda K, Nagib S. Dahdah, Fouron JCFCardiovascular evaluation of fetal anemia due to alloimmunization. Fetal Diagnosis and TherapyF(2007 in press)
  12. Suda K, Matsumura M, Miyanishi SFIntermittent heparin infusion in small children with ischemic heart disease caused by Kawasaki disease. Int J CardiolF(2007 in press)
  13. Kanahara M, Kai H, Toyomasu K, Yoshida T, Hiraki T, Sagawa K, Imaizumi T: Characteristic features of QRST integral mapping in patients with high-risk Brugada syndrome. Circ J 71 (1):63-69,2007.1
  14. Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, Hirai Y, Imaizumi T: Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery. - An epidemiological study - Atherosclerosis 191(1):206-210,2007.3
  15. Aicher A, Rentsch M, Sasaki K, Ellwart JW, Fandrich F, Siebert R, Cooke JP, Dimmeler S, Heeschen C: Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res 100(4): 581-589,2007.3
  16. Koga M, Kai H, Yasukawa H, Kato S, Yamamoto T, Kawai Y, Kusaba K, Seki Y, Kai M, Egashira K, Kataoka Y, Imaizumi T: Postnatal blocking of interferon-ƒÁ function prevented atherosclerotic plaque formation in apolipoprotein E-knockout mice. Hypertens Res 30(3):259-267,2007.3
  17. Kusaba K, Kai H, Koga M, Takayama N, Ikeda A, Yasukawa H, Seki Y, Egashira K, Imaizumi T: Inhibition of intrinsic interferon-ƒÁ function prevents neointima formation after balloon injury. Hypertension 49(4):909-915,2007.4
  18. Tahara N, Kai H, Yamagishi S, Mizoguchi M, Nakaura H, Ishibashi M, Kaida H, Baba K, Hayabuchi N, Imaizumi T: Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 49(14):1533-1539,2007.4
  19. Yamagishi S, Matsuoka H, Kitano S, Hibi N, Jinnouchi Y, Umei H, Iida S, Takenaka K, Matsui T, Nakamura K, Imaizumi T: Elevated circulating oxidized LDL levels in Japanese subjects with the metabolic syndrome. Int J Cardiol 118(2):270-272,2007.5
  20. Haramaki N, Ikeda H, Takenaka K, Katoh A, Sugano R, Yamagishi S, Matsuoka H, Imaizumi T: Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: Possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol 27(6):1471-1477,2007.6
  21. Hino A, Adachi H, Enomoto M, Furuki K, Shigetoh Y, Ohtsuka M, Kumagae S, Hirai Y, Jalaldin A, Satoh A, Imaizumi T: Habitual coffee but not green tea consumption is inversely associated with metabolic syndrome. - An epidemiological study in a general Japanese population. Diabetes Res Clin Pract 76(3):383-389,2007.6
  22. Saito Y, Sasaki K, Katsuda Y, Murohara T, Takeshita Y, Okazaki T, Arima K, Katsuki Y, Shintani S, Shimada T, Akashi H, Ikeda H, Imaizumi T: Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease. Circ J 71(8):1187-1192,2007.8
  23. Koga M, Kai H, Yasukawa H, Yamamoto T, Kawai Y, Kato S, Kusaba K, Kai M, Egashira K, Kataoka Y, Imaizumi T: Inhibition of progression and stabilization of plaques by postnatal interferon-ƒÁ function blocking in ApoE-knockout mice. Circ Res 101(4):348-356,2007.8
  24. Tahara N, Kai H, Nakaura H, Mizoguchi M, Ishibashi M, Kaida H, Baba K, Hayabuchi N, Imaizumi T: The prevalence of inflammation in carotid atherosclerosis-analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J 28(18):2243-2248,2007.9
  25. Nakamura K, Yamagishi S, Matsui T, Yoshida T, Takenaka K, Jinnouchi Y, Yoshida Y, Ueda S, Adachi H, Imaizumi T: Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol 170:2159-2170,2007
  26. Hoshino T, Kato S, Oka N, Imaoka H, Kinoshita T, Takei S, Kitasato Y, Kawayama T, Imaizumi T, Yamada K, Young HA, Aizawa H: Pulmonary inflammation and enphysema. Role of cytokines IL-18 and IL-13. Am J Respir Crit Care Med 176:49-62,2007
  27. Saito I, Tsushima M, Sato S, Nakamura M, Kokubo Y, Mannami T, Adachi H, Konishi M, Okada K, Iso H, Kario K, Ohsuzu F, Momiyama Y: A low level of C-reactive protein in Japanese adults and its association with cardiovascular risk factors: the Japan NCVC- collaborative inflammation cohort (JNIC) Study. Atherosclerosis 194:238-244,2007
  28. Jinnouchi Y, Yamagishi S, Matsui T, Takenaka K, Yoshida Y, Nakamura K, Ueda S, Imaizumi T: Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice. Brain Res 1167:92-100,2007
  29. Yoshida Y, Yamagishi S, Matsui T, Nakamura K, Imaizumi T, Yoshimura K, Yamakawa R: Increased levels of pigment epithelium-derived factor in aqueous humor of patients with uveitis. Br J Ophthalmol 91:149-150,2007
  30. Yokoi M, Yamagishi S, Takeuchi M, Matsui T, Yoshida Y, Ohgami K, Amano-Okamoto T, Ohno S: Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation. Br J Ophthalmol 91:397-398,2007
  31. Yoshida Y, Yamagishi S, Matsui T, Nakamura K, Imaizumi T, Yoshimura K, Yamakawa R: Positive correlation between pigment epithelium-derived factor and monocyte chemoattractant protein-1 levels in the aqueous humour of patients with uveitis. Br J Ophthalmol 91:737-738,2007
  32. Yokoi M, Yamagishi S, Saito A, Yoshida Y, Matsui T, Saito W, Hirose S, Ohgami K, Kase M, Ohno S: Positive association of pigment epithelium-derived factor with total anti-oxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 91:885-887,2007
  33. Yoshida Y, Yamagishi S, Matsui T, Nakamura K, Imaizumi T, Yoshimura K, Yamakawa R: Positive correlation of pigment epithelium-derived factor and total antioxidant capacity in aqueous humour of patients with uveitis and proliferative diabetic retinopathy. Br J Ophthalmol 91:1133-1134,2007
  34. Kajimoto H, Hashimoto K, Bonnet SN, Haromy A, Harry G, Moudgil R, Nakanishi T, Rebeyka I, Thebaud B, Michelakis ED, Archer SL: Oxygen activates the Rho/Rho-kinase pathway and induces RhoB and ROCK-1 expression in human and rabbit ductus arteriosus by increasing mitochondria-derived reactive oxygen species: a newly recognized mechanism for sustaining ductal constriction. Circulation 115:1777-1788,2007
  35. Kajimoto H, Nakazawa M, Murasaki K, Mori Y, Tanoue K, Kasanuki H, Nakanishi T: Increased thrombogenesity in patients with cyanotic congenital heart disease. Circ J 71:948-953,2007
  36. Miyata E, Satoh S, Inokuchi K, Aso A, Kimura Y, Yokoyama S, Mori E, Nakamura T, Matsumoto M, Fujino Y, Kishihara Y, Uda K, Takemoto K, Inoue T, Nakayama S, Kobayashi R, Uesugi N, Hiyamuta K: Three fatal cases of rapidly progressive infective endocarditis caused by staphylococcus aureus. -One case with huge vegetation- Circ J 71:1488-1491,2007
  37. Sasayama S, Satoh T, Izumi T, Yoshida S, Kyotani S, Tahara N: Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients. Curr Med Res Opin 23(2):395-400,2007
  38. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T: Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 23(5):368-371,2007
  39. Unoki H, Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito Y: Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of reactive oxygen species in adipocytes. Diabetes Res Clin Prac 76:236-244,2007
  40. Menotti A, Lanti M, Kromhout D, Blackburn H, Nissinen A, Dontas A, Kafatos A, Nedeljkovic S, Adachi H: Forty-year coronary mortality trends and changes in major risk factors in the first 10 years of follow-up in the seven countries study. Eur J Epidemiol 22:747-754,2007
  41. Kawaguti Y, Toyomasu K, Yoshida N, Baba K, Uemoto M, Minota S: Measuring job among hospital nurses: An attempt to identify biological markers. Fukuoka Acta Medica 98(2):48-55,2007
  42. Yamagishi S, Nakamura K, Matsui T, Yoshida T, Takeuchi M, Imaizumi T: Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro. Horm Metab Res 39:233-235,2007
  43. Yamagishi S, Adachi H, Takeuchi M, Enomoto M, Furuki K, Matsui T, Nakamura K, Imaizumi T: Serum level of advanced glycation end-products(AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res 39:845-848,2007
  44. Matsumoto Y, Ueda S, Yamagishi S, Matsuguma K, Shibata R, Fukami K, Matsuoka H, Imaizumi T, Okuda S: Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 18:1525-1533,2007
  45. Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, Ochi H, Nonaka M, Nabeshima Y, Inoue M, Ishitobi T, Chayama K, Tazuma S: Elevated levels of serum advanced glycation end products in patients with nonalcoholic steatohepatitis. J Gastroenterology and Hepatology 22:1112-1119,2007
  46. Ihara Y, Egashira K, Nakano K, Ohtani K, Kubo M, Koga J, Iwai M, Horiuchi M, Gang Z, Yamagishi S, Sunagawa K: Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. J Mol Cell Cardiology 43:455-464,2007
  47. Yamagishi S, Matsui T, Nakamura K, Yoshida T, Takeuchi M, Inoue H, Yoshida Y, Imaizumi T: Pigment epithelium-derived factor (PEDF) suppresses expression of receptor for advanced glycation end products (RAGE) in the eye of diabetic rats. Ophthalmic Res 39:92-97,2007
  48. Yokosuka K, Park JS, Jimbo K, Yoshida T, Yamada K, Sato K, Takeuchi M, Yamagishi S, Nagata K: Immunohistochemical demonstration of advanced glycation end products and the effects of advanced glycation end products in ossified ligament tissues in vitro. Spine 32:E337-339,2007
  49. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Makino T, Shimizu T, Sata M: Atorvastatin inhibits advanced glycation end products (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing reactive oxygen species generation. Vascular Disease Prevention 4:213-216,2007
  50. Kaneyuki U, Ueda S, Yamagishi S, Kato S, Fujimura T, Shibata R, Hayashida A, Yoshimura J, Kojiro M, Oshima K, Okuda S: Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascular Pharmacology 46:286-292,2007
  51. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Jinnouchi Y, Yoshida Y, Ueda S, Katsuki Y, Katsuda Y, Imaizumi T: Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: A possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis:(in press)
  52. Koga M, Kai H, Egami K, Murohara T, Ikeda A, Yasuoka S, Egashira K, Matsuishi T, Kai M, Kataoka Y, Kuwano M, Imaizumi T: Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Comm:(in press)
  53. Takeshita Y, Katsuki Y, Katsuda Y, Kai H, Saito Y, Arima K, Sasaki K, Imaizumi T: Vitamin C reversed malfunction of peripheral blood-derived mononuclear cells in@smokers through antioxidant property. Circ J:(in press)
  54. Inage T, Yoshida T, Hiraki T, Ohe M, Takeuchi T, Nagamoto Y, Fukuda Y, Gondo T, Imaizumi T: Chronic cardiac resynchronization therapy reverses cardiac remodeling and improves invasive hemodynamics of patients with severe heart failure on optimal medical treatment. Europace:(in press)
  55. Ohe M, Yoshida T, Hiraki T, Matsumoto M, Otsubo H, Inage T, Imaizumi T: Detection of coronary artery stenosis after successful percutaneous coronary intervention by dipyridamole stress portable type signal-averaged electrocardiography. - A prospective study - Heart and Vessels:(in press)
  56. Fukuda Y, Yoshida T, Inage T, Takeuchi T, Nagamoto Y, Gondo T, Imaizumi T: Implantation of pacemaker for sick sinus syndrome in patient with persistent left superior vena cava and absent right superior vena cava. Heart and Vessels:(in press)
  57. Enomoto M, Adachi H, Fukami A, Furuki K, Satoh A, Otsuka M, Kumagae S, Nanjo Y, Shigetoh Y, Imaizumi T: Serum dehydroepiandrosteone sulfate levels predict longevity in men. - 27-year follow-up study in a community-based cohort (Tanushimaru study) - J Am Geriatr Soc:(in press)
  58. Honda A, Abe R, Makino T, Norisugi O, Fujita Y, Watanabe H, Nishihira J, Iwakura Y, Yamagishi S, Shimizu H, Shimizu T: Interleukin-1? and macrophage migration inhibitory factor (MIF) in dermal fibroblasts mediate UVA-induced matrix metalloproteinase-1 expression. J Dermatol Sci:(in press)
  59. Tanaka K, Ichiyama K, Hashimoto M, Yoshida H, Takimoto T, Takaesu G, Torisu T, Hanada T, Yasukawa H, Fukuyama S, Inoue H, Nakanishi Y, Kobayashi T, Yoshimura A: Loss of SOCS1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFNƒÁ on STAT3 and Smads. J Immunol:(in press)
  60. Th?baud B, Wu XC, Kajimoto H, Bonnet S, Hashimoto K, Michelakis ED, Archer SL: Developmental absence of the O2 sensitivity of L-type calcium channels in preterm ductus arteriosus smooth muscle cells impairs O2 constriction contributing to patent ductus arteriosus. Pediatr Res:(in press)
  61. Kanahara M, Kai H, Okamura T, Wada T, Suda K, Imaizumi T, Sagawa K: Usefulness of high concentration calcium chloride solution for correction of activated partial thromboplastin time (APTT) in patients with high hematocrit value. Thromb Res:(in press)

˜a•¶˜_•¶

  1. –ö¬–¾A‹gìˆê—mF‘å“®–¬•Ù–ŒÇ‚É‚¨‚¯‚élH•Ù‚Ì‘I‘ð-‹@ŠB•Ù‚©¶‘Ì•Ù‚©- “ú–{ŠO‰ÈŠw‰ïŽGŽF59-63,2007
  2. –¾Î‰prF‹}«‘å“®–¬‰ð—£. ‹~‹}ˆãŠwF379-385,2007
  3. “c’†ŒúŽõA–ö¬–¾F• •”‘å“®–¬áŽ‚ɑ΂·‚éEndovascular aneurysm repair(EVAR). International Review of ThrombosisF54-56,2007
  4. ‘O–ì‘׎÷C_ŒË‘¾˜YCœA£²ŽqC•P–ì˜a‰ÆŽqCŠÝ–{T‘¾˜YCâÄŽè“c—Y‰îC“¡–ì_C{“cŒ›Ž¡C—Ñ—´”V‰îC–x‘å‘ C‰Ã‘º•qŽ¡C¼Î–LŽŸ˜YFŽY‰ÈŠO—ˆ‚Å‚Ì‘ÙŽ™SƒGƒR[ŠO—ˆŠJÝ‚Ææ“V«SŽ¾Š³‚Ì‘ÙŽ™f’fó‹µ. ¬Ž™zŠÂŠíŠw‰ïŽGŽF23F14-18,2007
  5. ‘O–ì‘׎÷C‰ª“cƒˆê˜YC_ŒË‘¾˜YCL£²ŽqC_“c@—mC“¡–ì@_CŠâ“c‰¢‰îC{“cŒ›Ž¡C¼Î–LŽ¡˜YF“û—cŽ™‚ÌS‘Ÿ‚ÆSIDSD “ú–{SIDSŠw‰ïŽGŽF7F23-26,2007
  6. ‰–Œ©‰ÄŽqCŽR’†’‰‘¾˜YC“ì•”Œõ•FC’·–å‰ëŽqC{“cŒ›Ž¡CV‘Œ°C¼‘º³•FC‚‹´‘׶C‘¾“c@–ÎFˆÓŽ¯áŠQCŒÄ‹záŠQCŠJŠá¢“ï‚𔺂Á‚½overlap Stevens-Johnson syndrome and toxic epidermal necrolysis‚Ì1’jŽ™—áD “V—ˆãŠw‹I—vF10i1jF94-101,2007
  7. àV“c—Y‰FA“¿‰iŽ •FAì—Ç•”üA‰Í–ì’ÊFA‚£’J“OA¼–{‚GA—â–´“c_ŽiAX“c–ÎŽ÷FŠ¥“®–¬ƒoƒCƒpƒXpŒã‚̓«S–[ד®‚ɃtƒŒƒJƒCƒjƒh‚ª’˜Œø‚µ‚½ˆê—á. ˆãŠw‚Æ–òŠwF57:389-393,2007
  8. ŒÃ‰ê‹`‘¥FŽ¸_‚Ìf’fEŽ¡—ÃKƒCƒhƒ‰ƒCƒ“ 9.S‹ØÇ Circ J@71(suppl IV): 1070-1072, 2007
  9. ’†‘ºr”ŽA–ƒ¶–¾Œ©A—â–´“c_ŽiFƒy[ƒXƒ[ƒJ[Až‚Ýp‚É‚¨‚¯‚é–TƒqƒX‘©ƒy[ƒVƒ“ƒO‚ÌŽŽ‚Ý. Therapeutic ResearchF28:578-582,2007
  10. ‰|–{”ü‰ÀA‘«’B@ŽõFˆê”ÊZ–¯‚ð‘ÎÛ‚Æ‚µ‚½‰uŠw“IŒ¤‹†‚©‚çI––“œ‰»ŽY•¨(AGEs)‚ͶŠˆKŠµ•a‚Ìi“WE—\–h‚Ì—\’mˆöŽq‚ƂȂ蓾‚é‚©H ‘æ22‰ñŒ’Nˆã‰ÈŠwŒ¤‹†•¬˜_•¶WF1-6,2007
  11. ‘«’B@ŽõF¬l•aA“Á‚É”]ESŒŒŠÇ•a‚ð—\–h‚·‚éN-3ŒnŽ‰–bŽ_‚Ì–ðŠ„‚ÌŒ¤‹†. ‘æ52‰ñŽÐ‰ïŒú¶Ž–‹Æ•¬AˆãŠwŒ¤‹†•ñWF115-117,2007
  12. ‰|–{”ü‰ÀA‘«’B@ŽõFI––“œ‰»ŽY•¨(AGEs)‚Í“œ”A•aE“®–¬d‰»«Ž¾Š³‚Ìi“WE—\–h‚Ì—\’mˆöŽq‚ƂȂ蓾‚é‚©Hˆê”ÊZ–¯‚ð‘ÎÛ‚Æ‚µ‚½‰uŠw“IŒ¤‹†‚©‚çA¶ŠˆKŠµ•a—\–h‚ðŒŸ“¢ \ ‘æ22‰ñiàj‘‡Œ’N„ià’cF1-8,2007
  13. ‰|–{”ü‰ÀFPositive association of serum levels of advanced glycation end products with thrombogenic markers in humans. –¢•a‚ÆR˜V‰»F16(1):66-71,2007
  14. Ÿ“c—m•ãA’|‰º‹g–¾A—L”n@Œ’AâV“¡@—TAŒŽ—^Žu•vAŠOŽRN”VA²X–ØŒ’ˆê˜YA¡ò@•×FŽ©ŒÈœ‘’PŠj‹…ˆÚA‚ƃvƒƒXƒ^ƒOƒ‰ƒ“ƒfƒBƒ“•¹—p—Ö@. Pharma MedicaF25F101-1042007
  15. ¼–{@ŠwA‘å‰ê‰ëMAX@—T”VA㑺t•áAˆî–Ñ’qmA¡ò@•×F—\–h“IICDAž‚ÝŒã5”N–ڂʼn‚ß‚ÄSŽº×“®‚ɑ΂µ‚Äì“®‚µ‚½‰Æ‘°«Šg’£Œ^S‹ØÇ‚Ì1—á. J CardiolF(in press)
  16. ˆÀìG—YA‘åê–LŽ¡A”n“nˆêŽõA¡ò@•×FS•s‘S‚Ì•a‘Ô‚É‚¨‚¯‚éJAKƒVƒOƒiƒ‹§Œä‚Ì–ðŠ„A-Negative Regulation of JAK Signaling and Cardiac Injury- S‘ŸF(in press)
  17. b”ã‹vŽjA¡ò@•×F‚—p—ʃXƒgƒƒ“ƒOƒXƒ^ƒ`ƒ“•ž—p‚ð•K—v‚Æ‚·‚é“«‚LDLƒRƒŒƒXƒeƒ[ƒ‹ŒŒÇ‚ɑ΂·‚éƒGƒ[ƒ`ƒ~ƒuŠu“ú“Š—^•¹—p—Ö@‚Ì—L—p«. Progress in MedicineF(in press)
  18. b”ã‹vŽjFŽ¡—Ã’ïR«‚LDLƒRƒŒƒXƒeƒ[ƒ‹ŒŒÇ‚ɑ΂·‚éƒAƒvƒ[ƒ`. Medical PracticeF(in press)

Ç—á•ñ

  1. T.Takaseya, S.Hiromatsu, H.Akashi, T.Okazaki, S.Tobinaga, S.AoyagiF A Case of@Unilateral Leg Edema Due to Abdominal Aortic Aneurysm with Aortocaval Fistula. Ann Thorac Cardiovasc SurgF135-138,2007
  2. E.Tayama, S.Chihara, S.Fukunaga, H.Akashi, S.Aoyagi, K.MizoguchiF Embolic Myocardial Infaction and Left Ventricular Rupture Due to Mital Valve Endocarditis. Ann Thorac Cardiovasc SurgF206-208,2007
  3. S.Hiromatsu, Y.Hosokawa, N.Egawa, H.Yokokura, K.Akaiwa, S.AoyagiF Strategy for isolated iliac artery@aneurysm. Asian Cardiovasc Thorac AnnF280-284,2007
  4. S.Aoyagi, S.Fukunaga, E.Tayama, E.Nakamura, N.Egawa, Y.HosokawaF Benefits of a ƒÀ-Blocker for Intractable Hemolysis due to Paraprosthetic Leakage. Asian Cardiovasc & Thorac AnnF441-443,2007
  5. S.Hiromatsu, Y.Hosokawa, N.Egawa, S.AoyagiFSpontaneous repture of the dorsalis artery : report of a case. Ann Thorac Cardiovasc SurgF290-292,2007
  6. S.Aoyagi, S.Fukunaga, E.Tayama, H.Hori, K.YoshikawaF Prosthetic valve thrombosis in the aortic position. ChirurgiaF25-28,2007
  7. Ÿ“c—m•ãA—L”n@Œ’AÖ“¡@—TAŠOŽRN”VAŒŽ—^Žu•vA²X–ØŒ’ˆê˜YA¡ò@•×FŽ©ŒÈœ‘’PŠj‹…ˆÚA‚É‚æ‚édÇ‹•ŒŒŽˆ‚ÌŽ¡—ÃFŽ¡—ÃŒø‰Ê‚ɑ΂·‚é‰e‹¿ˆöŽq‚ɂ‚¢‚Ä‚ÌŒŸ“¢. –¬ŠÇŠw@47(2)F221-225,2007.4
  8. Š}Œ´–¾ŽqA“cŒ´éLAaŒûƒ~ƒmƒŠA”~ˆäG˜aA²X–ØŒ’ˆê˜YA‚éŠì“TA΋´³•qA¡ò@•×FSƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ìf’f‚¨‚æ‚ÑŽ¡—ÃŒø‰Ê”»’è‚É18F-fluorodeoxyglucose positron emission tomography‚ª—L—p‚Å‚ ‚Á‚½1—á. S‘Ÿ@39(12)F1064-1070,2007.12

‘à

  1. Yamagishi S, Matsui T, Ueda S, Nakamura K, Imaizumi T: Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes. Cardiovascular & Hematological Agents in Medicinal Chemistry 5: 236-240, 2007
  2. Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S: Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clinical Experimental Nephrology 11: 115-121,2007
  3. Yamagishi S, Nakamura K, Matsui T, Yoshida Y, Takenaka K, Jinnnouchi Y, Imaizumi T: Signal transduction therapy of diabetic vascular complication. Current Signal Transduction Therapy 2: 91-100,2007
  4. Fukami K, Yamagishi S, Ueda S, Okuda S: Novel therapeutic targets for diabetic nephropathy. Endocrine, Metabolic & Immune Disorders-Drug Targets 7: 83-92,2007
  5. Yamagishi S, Nakamura K, Matsui T, Ueda S, Imaizumi T: Role of postprandial hyperglycemia in cardiovascular disease in diabetes. Int J Clin Pract 61: 83-87,2007
  6. Abe R, Fujita Y, Yamagishi S: Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini-Reviews in Medicinal Chemistry 7: 649-661,2007
  7. “cŒ´éLAaŒûƒ~ƒmƒŠA¡ò@•×F18FDG-PET‚É‚æ‚é–ò•¨—Ö@‚ÌŒø‰Ê”»’è. The Lipid 18(1)F71-78,2007.1
  8. âV“¡@—TAŸ“c—m•ãA¡ò@•×F‹•ŒŒ«SŽ¾Š³‚̃vƒ‰ƒCƒ}ƒŠƒPƒA. —Õଂƌ¤‹†@84(1)F7-12,2007.1
  9. ŒÃ–Ø‹v”üŽqA¼‰ªG—mA‘«’B@ŽõA¡ò@•×FNO‡¬‘jŠQ•¨Ž¿ADMA. zŠÂŠí‰È61(2)F144-151,2007.2
  10. ‘ê@Œ’Ab”ã‹vŽjA¡ò@•×FŠ¥“®–¬d‰»‚Æ‚ŒŒˆ³-Šî‘b. “®–¬d‰»—\–h6(1)F28-33,2007.4
  11. b”ã‹vŽjF“®–¬d‰»ŠwUPDATE-“®–¬d‰»‚̬‚è—§‚¿‚ð—‰ð‚·‚éDFDG-PET-“®–¬d‰»ƒvƒ‰[ƒN‚̉ŠÇ‚ð‚Ý‚éD ˆãŠw‚Ì‚ ‚ä‚Ý@221 (13)F1258-1262, 2007.6
  12. ²“¡@WA‘å“à“c¹’¼A¡ò@•×FANP»Ü-ƒ¿Œ^ƒqƒgS–[«ƒiƒgƒŠƒEƒ€—˜”Aƒyƒvƒ`ƒh»ÜihANPj‚̶—Šw“I“Á«‚Æ‹}«S•s‘S‚É‚¨‚¯‚éŽg—p–@. f’f‚ÆŽ¡—à 95(10)F1751-1756,2007.10
  13. ‰|–{”ü‰ÀA¡ò@•×FƒfƒqƒhƒƒGƒsƒAƒ“ƒhƒƒXƒeƒƒ“iDHEAj‚ÆŽõ–½. ŒŸ¸‚Æ‹Zp@35(12)F1399-1401,2007.11
  14. —L”n@Œ’AŸ“c—m•ãA¡ò@•×FŒŒŠÇĶ‚Æ‹•ŒŒ«––½_ŒoáŠQ‚ÌŽ¡—Ã. Heart View 11(13)F1446-1451,2007.12
  15. ¼‰ªG—mFŽ_‰»ƒXƒgƒŒƒX. ˆãŠw‚Ì‚ ‚ä‚Ý@“®–¬d‰»update@221:1215-1218,2007
  16. ^è’¼ŽqA–L‘Œ÷ŽŸF¸_áŠQŠ³ŽÒ‚ª’nˆæ‚ŶŠˆ‚·‚邽‚߂̎ЉŽ¿Ž‘Œ¹‚Ì•K—v—ʂɂ‚¢‚Ä‚ÌŒŸ“¢. ‹v—¯•ÄˆãŠw‰ïŽGŽ@70(8)F241|248,2007
  17. ^è’¼ŽqA–L‘Œ÷ŽŸF_Œo“ï•aŠ³ŽÒiÒ‘¬”]•Ï«Çj‚ÌQOL‚Æ•ÛŒ’•ŸŽƒƒT[ƒrƒX‚̃j[ƒY‚ÉŠÖ‚·‚錤‹†D ‹v—¯•ÄˆãŠw‰ïŽGŽ@70(8)F249|258,2007
  18. –L‘Œ÷ŽŸA“c’†–M–¾A‰Á“¡’‰•FFƒTƒvƒŠƒƒ“ƒgÛŽæ‚É‚æ‚é˜J“­ŽÒƒXƒgƒŒƒXƒ}ƒl[ƒWƒƒ“ƒg‚ÌŽŽ‚ÝD ‹v—¯•ÄˆãŠw‰ïŽGŽ@70(8)F260|266,2007
  19. ’r“c‹v—YAŽR–{–M•FA‰Á“¡GŽiA–{ŠÔ—FŠîAX“c‹±‘ãFƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚ðl—¶‚µ‚½‚ŒŒˆ³Ž¡—Â̂ ‚è•û. ŒŒˆ³@14:95-102,2007
  20. “cŒ´éLAaŒûƒ~ƒmƒŠA¡ò@•×F•sˆÀ’èƒvƒ‰[ƒN‚̉摜f’f. ŒÄ‹z‚ÆzŠÂ Bedside Teaching@55(11):1255-1259,2007
  21. —â–´“c_ŽiFˆãŽt‚Ì—§ê‚©‚ç‚Ý‚½Š³ŽÒ–Úü‚̈ã—Ã. ‘—§ˆã—Êw‰ïŽˆã—Ã@61:473-476,2007
  22. “cŒ´éLAaŒûƒ~ƒmƒŠA¡ò •×F•ªŽqƒCƒ[ƒWƒ“ƒO‚É‚æ‚éSŒŒŠÇ•a‚Ìf’f. THE CIRCULATION FRONTIER 11(2): 28-35,2007.6 ¼‰ªG—mF“®–¬d‰»ƒTƒƒQ[ƒgƒ}[ƒJ[‚Ì‚ ‚è‚©‚½. zŠÂŠí‰È@61:103-108,2007
  23. ’r“c‹v—YFƒAƒeƒ[ƒ€ŒŒðǂ̕“IŽ¡—Ãí—ª Šª“ªŒ¾. zŠÂŠí‰È@62:295-296,2007
  24. ‹g“c“TŽqA’r“c‹v—YFƒAƒeƒ[ƒ€ŒŒðǂ̕“IŽ¡—Ãí—ª ¶ŠˆKŠµ‰ü‘P‚É‚æ‚é—\–h|‰^“®—Ö@| zŠÂŠí‰È@62:314-320,2007
  25. —â–´“c_ŽiFƒWƒFƒlƒŠƒbƒNˆã–ò•i‚ÆŒö“I•a‰@‚Ì—§ê. Ž¡—Ã@89:561-565,2007
  26. ã“c½“ñA¼‰ªG—mA‰œ“c½–çFADMAFSt˜AŠÖ‚ð‰ð‚­V‚µ‚¢•ªŽq•W“I. Ž¡—Êw@41:96-100,2007
  27. ‘ê@Œ’A‹T”ö@PA‰i“c—²MA‰i–ì^Šì—YAŠâ‹´³lA‹Ê’u´ŽuFƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Žó—e‘Ì‘jŠQ–òiARBj“Š—^Œã‚É‹}«t•s‘S‚ð’悵‚½”n’ût‚Ì‚PÇ—á. “ú–{“à‰ÈŠw‰ïŽGŽ@96:1195-1198,2007
  28. “c’†–M–¾A–L‘Œ÷ŽŸAŒG–{³ˆê˜YFŒy“xÁ‰»ŠÇQOL•s’²‚ð‘i‚¦‚é‹Î–±˜J“­ŽÒ‚ւ̃TƒvƒŠƒƒ“ƒguƒŠƒZƒbƒg”üŠˆv“Š—^‚̉e‹¿D “ú–{–¢•aƒVƒXƒeƒ€Šw‰ïŽ@13(1)F101|103,2007
  29. H“¡”ŽŽiAb”ã‹vŽjA¡ò@•×FS‹ØƒŠƒ‚ƒfƒŠƒ“ƒOD “ú–{—Õà¬65(‘Š§)uS•s‘Siãj-ÅV‚ÌŠî‘bE—Õଌ¤‹†‚Ìi•à-v:302-306,2007
  30. b”ã‹vŽjA“cŒ´éLA¡ò@•×F“®–¬d‰»ƒvƒ‰[ƒNŠˆ“®«‚ðFDG-PET‚µ‚¤‚é‚©. ”]‘²’† 29(6)F819-823,2007
  31. ŒÃ‰ê‹`‘¥F‘æ11‰ñƒAƒ~ƒIƒ_ƒƒ“Œ¤‹†‰ïu‰‰WFS‹ØÇ‚É‚¨‚¯‚éƒAƒ~ƒIƒ_ƒƒ“‚ÌŽg—pŒoŒ±. Progress in Medicine ‘Š§†@27: 848-850,2007
  32. —â–´“c_ŽiFzŠÂŠíf—ÂÌÅ‘Oü. •ªŽqŒŒŠÇ•a@8:84-89,2007
  33. b”ã‹vŽjA“cŒ´éLA¡ò@•×F“®–¬d‰»Šˆ“®«‚ÌV‚µ‚¢•]‰¿–@-FDG-PET‚É‚æ‚錟“¢- –¬ŠÇŠw 47(3)F319-325,2007
  34. Š}@O‰ÀAŒÃ‰ê‹`‘¥FS‹ØÇ‚Ì’è‹`‚Æ•ª—Þ. Medical Technology@35:1224-1228,2007
  35. ¼‰ªG—mFŒŒ’†ƒ}[ƒJ[. Mebio@24:76-81,2007
  36. ¼‰ªG—mFSŒŒŠÇ—Õ°ŽŽŒ±‚É‚¨‚¯‚éƒTƒƒQ[ƒgƒ}[ƒJ[‚ɂ‚¢‚Ä. —Õ°–ò—@38:91S-92S,2007
  37. ¼‰ªG—mAA“c^ˆê˜YA“Œ@KmA–ìoFˆêFSŒŒŠÇ•aƒTƒƒQ[ƒgƒ}[ƒJ[‚Æ‚µ‚Ä‚Ìflow-mediated vasodilation‘ª’è‚Æ‚»‚Ì•W€‰»ˆÄ. —Õ°–ò—@38:305-309,2007

‘ÛŠw‰ï

  1. 15th Annual Meeting of Asian Society for Cardio-Vascular Surgery, Beijing China,May 17-20,2007
    N.Egawa, S.Hiromatsu, K.Ishihara, K.Akaiwa, Y.Hosokawa, E.Nakamura, A.Tanaka,H.Akashi, S.AoyagiFEnsuring perioperative safety in patients with deep venous thrombosis by placing a nonpermanent vena cava filter prior to elective surgery.
  2. The Society for Heart Valve Disease, New York, USA,June 15-18, 2007
    S.Fukunaga, H.Hori, K.Yoshikawa, T.Ueda, E.Tayama, S.AoyagiFThe Efficacy of Combined Surgery for Chronic Atrial Fibrillation and Mitral Valve Disease.
  3. 10th Annual meeting of the Korean society of ultrasound in obstetrics and gynecology , Korea Jeju ,October.20.2007
    Maeno YFPrenatal progression of the heart disease.
  4. 10th Annual meeting of the Korean society of ultrasound in obstetrics and gynecology , Korea Jeju ,October.20.2007
    Maeno YFPrenatal management of fetal arrhythmia.
  5. Annual Meeting of the American College of the Cardiology, New Orleans, USA,March 24-27,2007
    Suda K, Kudo K, Higaki T, Nomura Y, Miura M, Matsumura M, Ayusawa M, Ogawa S, and Matsuishi TFWarfarin Treatment in Patients with Giant Coronary Aneurysms Caused by Kawasaki Disease. |A Multi-Center Study -
  6. 3rd Congress of Asian Society for Pediatric Research,Tokyo,October 6-8, 2007
    Itoh S, Suda K, Kishimoto S, Koteda Y, Ishii H, Kudo Y, Nishino H, Yoshimoto H, Mukae T, Iemura M, Matsuishi TFHomodynamic changes before and intravenous gamma globulin infusion in patients with Kawasaki syndrome.
  7. CardioRhythm 2007, Hong Kong, China, February 2-4, 2007
    Nakamura T, Aso A, Hiyamuta K: Para-Hisian Pacing for permanent pacemaker implantation in patients with normal intraventricular conduction.
  8. The 1st International Congress of Cardiomyopathies and Heart Failure (ICCHF2007), Kyoto, Japan, March 10-13, 2007
    Imaizumi T: Risk Factors of Death for Japanese HCM Patients
  9. The 1st International Congress of Cardiomyopathies and Heart Failure (ICCHF2007), Kyoto, Japan, March 10-13, 2007
    Kai H, Kudo H, Imaizumi T: Large pressure variability aggravates hypertensive cardiac remodeling- Role of perivascular inflammation-
  10. The 1st International Congress of Cardiomyopathies and Heart Failure (ICCHF2007), Kyoto, Japan, March 10-13, 2007
    Yasukawa H, Sugi Y, Fukui D, Futamata N, Kai H, Imaizumi T: Numbers of circulating dendritic cells are associated with cardiac injury and prognosis in patients with decompensated heart failure.
  11. American College of Cardiology, 56th Annual Scientific sessions, New Orleans, USA, March 24-27, 2007
    Tahara N, Mizoguchi M, Kai H, Ishibashi M, Imaizumi T: Simvastatin attenuates plaque inflammation evaluated by 18F-fluoro-2-deoxyglucose positron emission tomography.
  12. American College of Cardiology, 56th Annual Scientific sessions, New Orleans, USA, March 24-27, 2007
    Tahara N, Mizoguchi M, Kai H, Yamagishi S, Ishibashi M, Imaizumi T: Vascular inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography is strongly associated with the metabolic syndrome.
  13. 76th Annual European Atherosclerosis Society (EAS) Congress, Helsinki, Finland, June 10-13, 2007
    Enomoto M, Adachi H, Furuki K, Kumagae S, Otsuka M, Sigetoh Y, Fukami A, Satoh A, Imaizumi T: Impact of higher blood pressure on the risk of death in 27-year follow-up study.
  14. 76th Annual European Atherosclerosis Society (EAS) Congress, Helsinki, Finland, June 10-13, 2007
    Enomoto M, Adachi H, Furuki K, Kumagae S, Otsuka M, Sigetoh Y, Fukami A, Satoh A, Imaizumi T: Serum dehydroepiandrosterone sulfate levels predict longevity men (27-year follow-up study).
  15. 76th Annual European Atherosclerosis Society (EAS) Congress, Helsinki, Finland, June 10-13, 2007
    Kumagae S, Adachi H, Enomoto M, Satoh A, Fukami A, Otsuka M, Sigetoh Y, Furuki K, Imaizumi T: TGF-ƒÀ1 is a marker for left ventricular hypertrophy in hypertensive subjects in a general population.
  16. 76th Annual European Atherosclerosis Society (EAS) Congress, Helsinki, Finland, June 10-13, 2007
    Fukami A, Adachi H, Enomoto M, Kumagae S, Otsuka M, Shigetoh Y, Furuki K, Satoh A, Imaizumi T: The association between serum monocyte chemoattractant protein-1 (MCP-1) and the metabolic syndrome.
  17. Europace 2007, Lisbon, Portugal, June 24-27, 2007
    Inage T, Yoshida T, Takeuchi T, Nagamoto Y, Gondo T, Fukuda Y, Imaizumi T: Does cardiac resynchronization therapy prevent ventricular arrhythmias?
  18. Europace 2007, Lisbon, Portugal, June 24-27, 2007
    Inage T, Yoshida T, Takeuchi T, Nagamoto Y, Fukuda Y, Gondo T,@Imaizumi T: Dual-chamber pacing induced left ventricular remodeling for severe drug@refractory symptomatic obstructive hypertrophic cardiomyopathy.
  19. European Society of Cardiology (ESC) Congress 2007, Vienna, Austria, September 1-5, 2007
    Kudo H, Kai H, Takayama N, Mori T, Takemiya K, Ikeda A, Koga M, Imaizumi T: Exaggerated blood pressure variability aggravates hypertensive cardiac remodeling through the angiotensin‡U-mediated inflammation.
  20. European Society of Cardiology (ESC) Congress 2007, Vienna, Austria, September 1-5, 2007
    Takayama N, Kai H, Kudo H, Mori T, Fukui D, Takemiya K, Ikeda A, Imaizumi T: Simvastatin attenuates cardiac hypertrophy, but not myocardial fibrosis, in spontaneously hypertensive rats with and without large blood pressure variability.
  21. European Society of Cardiology (ESC) Congress 2007, Vienna, Austria, September 1-5, 2007
    Takemiya K, Kai H, Takayama N, Tahara N, Imaizumi T: Mesenchymal stem cell-based prostacyclin synthase gene therapy for monocrotaline-induced pulmonary hypertension.
  22. European Society of Cardiology (ESC) Congress 2007, Vienna, Austria, September 1-5, 2007
    Mizuta Y, Kai H, Mizoguchi M, Imaizumi T: Valsartan attenuated myocardial fibrosis and diastolic dysfunction of hypertensive hearts in humans. Assessments using integrated backscatter analysis.
  23. European Society of Cardiology (ESC) Congress 2007, Vienna, Austria, September 1-5, 2007
    Mori T, Kai H, Takayama N, Kudo H, Takemiya K, Ikeda A, Koga M, Imaizumi T: Estrogen withdrawal prolonged vascular inflammation and oxidative stress and aggravated diastolic function in pressure-overloaded female rats.
  24. 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 17-21, 2007
    Jinnouchi Y, Yamagishi S, Takeuchi M, Imaizumi T: Atorvastatin not only decreases serum levels of AGE in diabetic patients, but also inhibits the AGE-induced C-reactive protein expression in hepatoma dendritic cells.
  25. 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 17-21, 2007
    Yoshida Y, Yamagishi S, Matsui T, Yamakawa R, Imaizumi T: Pigment epithelium-derived factor protects against AGE- or diabetes-induced retinal derangement through its anti-oxidative properties expression.
  26. Asia-Pacific Atrial Fibrillation Symposium 2007, Taipei, Taiwan, October 18-20, 2007
    Nagamoto Y, Tsuchiya T, Ashikaga K, Narita S, Gondo T, Fukuda Y, Inage T, Yoshida T, Imaizumi T: The Sagittal bundle in the right atrial appendage as a slow conduction zone or block site in the superior aspect of the reentry circuit of common atrial flutter: A study using a noncontact mapping system.
  27. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Yasukawa H, Yamamoto T, Koga M, Sugi Y, Fukui D, Futamata N, Tahara N, Kai H, Oba T, Imaizumi T: Lacking SOCS3 gene in macrophages prevents the development of atherosclerosis in ApoE deficient mice.
  28. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Arima K, Katsuda Y, Saito Y, Katsuki Y, Sasaki K, Yamagishi S, Ikeda H, Kai H, Imaizumi T: Role of PEDF in regulation of skeletal blood flow and neovascularization in ischemic limb via interaction with VEGF.
  29. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Ikeda A, Kai H, Koga M, Imaizumi T: Interferon-gamma-induced CD40/CD40 ligand pathway activation mediates atherosclerotic plaque progression and destabilization in ApoE-knockout mice.
  30. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Kudo H, Kai H, Takayama N, Mori T, Sugi Y, Fukui D, Takemiya K, Ikeda A, Koga M, Hirooka Y, Imaizumi T: Blood pressure variability-induced aggravation of end-organ damages is another achievable target of hypertension treatment. -Effects of angiotensin receptor blocker on an animal model-
  31. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Jinnouchi Y, Yamagishi S, Matsui T, Nakamura K, Takenaka K, Yoshida Y, Ueda S, Imaizumi T: Administration of pigment epithelium-derived factor inhibits cold injury-induced brain edema in mice.
  32. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Sugi Y, Yasukawa H, Kai H, Fukui D, Futamata N, Mawatari K, Ohba T, Koga M, Imaizumi T: Circulating dendritic cells may play an important role in pathophysiology in heart failure in humans.
  33. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Futamata N, Yasukawa H, Sugi Y, Kai H, Fukui D, Mawatari K, Ohba T, Tahara N, Imaizumi T: Simvastatin suppresses dendritic cell-induced autoimmune myocarditis via inhibition of dendritic cell activation.
  34. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Yasuoka S, Kudo H, Kai H, Takayama N, Mori T, Sugi Y, Fukui D, Takemiya K, Ikeda A, Koga M, Hirooka Y, Imaizumi T: Blood pressure variability-induced aggravation of end-organ damages is another achievable target of hypertension treatment. -Effects of angiotensin receptor blocker on an animal model-
  35. The American Heart Association, The 80th Scientific Sessions, Orlando, USA, November 4-7, 2007
    Yajima T, Yasukawa H, Zhou H, Yajima T, Lim BK, Knowlton KU: Cardiac-Restricted Disruption of SOCS3 leads to dilated cardiomyopathy in a gp130 dependent manner.

‘“àŠw‰ï

  1. ‘æ37‰ñ@“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ïi2007”N2ŒŽ21-23“úF“Œ‹žj
    •Ÿ‰iŽüŽiA–x@‰pŽkA‹gìˆê—mA¬{‰ê’qˆêA猴VŒáA“cŽR‰hŠîA–¾Î‰prA–ö¬–¾F‘m–X•Ù‘Oë•a•Ï‚ɑ΂·‚éŒ`¬p‚ÌŒŸ“¢.
  2. ‘æ37‰ñ@“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ïi2007”N2ŒŽ21-23“úF“Œ‹žj
    “c’†ŒúŽõAÔŠâŒ\ˆêAÎŒ´Œ’ŽŸA”ò‰i@ŠoA’†‘º‰pŽiA×ìK•vA‰iì‹IŽqA˜a“cŽŠOAœA¼LˆêA–¾Î‰prA–ö¬–¾F“–‰@‚É‚¨‚¯‚é‘å“®–¬áŽ‚ɑ΂·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“à‘}p‚ÌŽ¡—ìÑi‹Ù‹}Ç—á‚ð’†S‚Éj
  3. ‘æ37‰ñ@“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ïi2007”N2ŒŽ21-23“úF“Œ‹žj
    ‹gìˆê—mA–x@‰pŽkA‰¡‘q‹`“TAA“c’mGA•Ÿ‰iŽüŽiA“cŽR‰hŠîA猴VŒáA”ö“c@‹BAÔ{WŽ¡A–¾Î‰prA–ö¬–¾FŠ¥“®–¬ƒoƒCƒpƒXp‚É‚¨‚¯‚鎩ŒÈŒŒ—AŒŒ‚ÌŒŸ“¢.
  4. ‘æ20‰ñ@“ú–{Ž©ŒÈŒŒ—AŒŒŠw‰ïŠwp‘‰ïi2007”N3ŒŽ9-10“úFVŠƒj
    ‹gìˆê—mA–x@‰pŽkA‰¡‘q‹`“TAA“c’mGA•Ÿ‰iŽüŽiA“cŽR‰hŠîA猴VŒáA”ö“c@‹BAÔ{WŽ¡A–¾Î‰prA–ö¬–¾FŠ¥“®–¬ƒoƒCƒpƒXp‚É‚¨‚¯‚鎩ŒÈŒŒ—AŒŒ‚ÌŒŸ“¢.
  5. ‘æ35‰ñ@“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ïi2007”N5ŒŽ23-25“úF–¼ŒÃ‰®j
    ”ò‰i@ŠoA–¾Î‰prAœA¼LˆêA“c’†ŒúŽõAÎŒ´Œ’ŽŸA˜a“cŽŠOA‰iì‹IŽqA×ìK•vA ’†‘º‰pŽiA–ö¬–¾F“–‰È‚É‚¨‚¯‚é‘S‹|•”‘å“®–¬’uŠ·p?ÇðÇ–hŽ~‚Ì‚½‚ß‚ÌH•v?
  6. ‘æ35‰ñ@“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ïi2007”N5ŒŽ23-25“úF–¼ŒÃ‰®j
    “c’†ŒúŽõA‹S’˽“ñAÔŠâŒ\ˆêA‘å’Ë—T”VA’†‘º‰pŽiA‰iì‹IŽqAÎŒ´Œ’ŽŸAœA¼LˆêA–¾Î‰prA–ö¬–¾F• •”‘å“®–¬áŽE’°œ“®–¬áŽ‚ɑ΂·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒgŽ¡—Ẩ“Šu¬Ñ–â‘è“_
  7. ‘æ35‰ñ@“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ïi2007”N5ŒŽ23-25“úF–¼ŒÃ‰®j
    ‰¡‘q‹`“TA“c’†ŒúŽõAÔŠâŒ\ˆêA‹S’˽“ñA˜a“cŽŠOAÎŒ´Œ’ŽŸAœA¼LˆêA–¾Î‰prA–ö¬–¾Fš\ŒŒ‚Å”­Ç‚µ‚½‹¹•”‘å“®–¬•a•Ï‚ɑ΂·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“à‘}pÇ—á ’†‘º‰pŽiA“c’†ŒúŽõAœA¼LˆêA•Ÿ‰iŽüŽiA“cŽR‰hŠîAÎŒ´Œ’ŽŸA‹S’˽“ñA”ò‰i@ŠoA ˜a“cŽŠOAÔŠâŒ\ˆêA‰iì‹IŽqA×ìK•vA–¾Î‰prA–ö¬–¾F ŒÇ—§«’°œ“®–¬áŽ‚ɑ΂·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“à‘}p
  8. ‘æ35‰ñ@“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ïi2007”N5ŒŽ23-25“úF–¼ŒÃ‰®j
    ‹S’˽“ñA“c’†ŒúŽõAÔŠâŒ\ˆêAœA¼LˆêAÎŒ´Œ’ŽŸA”ò‰i@ŠoA˜a“cŽŠOA‰iì‹IŽqA×ìK•vA’†‘º‰pŽiA–¾Î‰prA–ö¬–¾F‹¹•”‘å“®–¬lHŒŒŠÇ’uŠ·pŒã‚Ì•«‡•”‰¼«áŽ‚ɑ΂·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“à‘}p
  9. ‘æ35‰ñ@“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ïi2007”N5ŒŽ23-25“úF–¼ŒÃ‰®j
    œA¼LˆêAÎŒ´Œ’ŽŸA‰iì‹IŽqA×ìK•vA’†‘º‰pŽiA˜a“cŽŠOA”ò‰i@ŠoA‹S’˽“ñA“c’†ŒúŽõA–¾Î‰prA–ö¬–¾FˆêŽž“I‰º‘åÖ¬ƒtƒBƒ‹ƒ^[‚É‚æ‚é[•”Ö¬ŒŒðLJ•¹Š³ŽÒ‚ÌŽüpŠú”xÇð—\–h
  10. ‘æ35‰ñ@“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ïi2007”N5ŒŽ23-25“úF–¼ŒÃ‰®j
    ˜a“cŽŠOAœA¼LˆêAÎŒ´Œ’ŽŸA“c’†ŒúŽõA‰iì‹IŽqA×ìK•vA’†‘º‰pŽiAÔŠâŒ\ˆêA”ò‰i@ŠoA–¾Î‰prA–ö¬–¾FRutherford•ª—Þ‚É‚æ‚é”j—ô«• •”‘å“®–¬áŽ‚ÌŽèp¬Ñ
  11. ‘æ27‰ñ@“ú–{Ö¬Šw‰ïŠwp‘‰ïi2007”N6ŒŽ18-20“úF‹ž“sj
    ‰iì‹IŽqAœA¼LˆêA–¾Î‰prA“c’†ŒúŽõAÎŒ´Œ’ŽŸA‹S’˽“ñA”ò‰i@ŠoA˜a“cŽŠOA×ìK•vA’†‘º‰pŽiA–ö¬–¾F“–‰È‚É‚¨‚¯‚éŽüpŠú[•”Ö¬ŒŒðÇE”x“®–¬ÇðÇ—\–hƒ}ƒjƒ…ƒAƒ‹‚ÌŒŸ“¢
  12. ‘æ32‰ñ@“ú–{ŠO‰ÈŒn˜A‡Šw‰ïŠwpW‰ïi2007”N6ŒŽ22-23“úF“Œ‹žj
    “c’†ŒúŽõA‹S’˽“ñA”ò‰i@ŠoA’†‘º‰pŽiA×ìK•vA‰iì‹IŽqA˜a“cŽŠOAœA¼LˆêA–¾Î‰prA–ö¬–¾F‹¹•”‘å“®–¬áŽ‚ɑ΂·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“à‘}p
  13. ‘æ32‰ñ@“ú–{ŠO‰ÈŒn˜A‡Šw‰ïŠwpW‰ïi2007”N6ŒŽ22-23“úF“Œ‹žj
    –¾Î‰prA•Ÿ‰iŽüŽiA“cŽR‰hŠîA”ò‰i@ŠoA–ö¬–¾F ‘å“®–¬Šî•”’uŠ·ŽèpFpŽ®‚Æ‚»‚̬Ñ
  14. ‘æ13‰ñ@“ú–{ŒŒŠÇ“àŽ¡—Êw‰ï‘‰ïi2007”N7ŒŽ28-29“úF“Œ‹žj
    ‹S’˽“ñA“c’†ŒúŽõA–¾Î‰prAœA¼LˆêA”ò‰i@ŠoA˜a“cŽŠOA‰iì‹IŽqA’†‘º‰pŽiA×ìK•vA–ö¬–¾FStent-Graft Migration
  15. ‘æ12‰ñ@“ú–{S‘ŸŒŒŠÇ–ƒŒŠw‰ïŠwp‘å‰ïi2007”N9ŒŽ15-16“úF•Ÿ‰ªj
    “cŽR‰hŠîFlHS”xƒ[ƒNƒVƒ‡ƒbƒvE‰ŠwŽÒ‚Ì‚½‚ß‚ÌCPB‘•ª‚©‚èuÀwIABP‚Ì—Õ°x
  16. ‘æ60‰ñ@“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïi2007”N10ŒŽ17-20“úFå‘äj
    A“c’mGA•Ÿ‰iŽüŽiAÔ{WŽ¡A¬{‰ê’qˆêA猴VŒáA”ö“c@‹BA“cŽR‰hŠîA–ö¬–¾F¶Žº‹@”\’ቺ‚𔺂¤’‹Œ«S‹Ø[ÇÇ—á‚ɑ΂·‚鶎ºŒ`¬p‚ÌŒŸ“¢
  17. ‘æ60‰ñ@“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïi2007”N10ŒŽ17-20“úFå‘äj
    –ö¬–¾FŠ´õ«S“à–Œ‰Š‚ÌŽ¡—Ãí—ª
  18. ‘æ48‰ñ@“ú–{–¬ŠÇŠw‰ï‘‰ïi2007”N10ŒŽ25-27“úF¼–{j
    –¾Î‰prA“c’†ŒúŽõA‹S’˽“ñA”ò‰i@ŠoAœA¼LˆêA•Ÿ‰iŽüŽiA“cŽR‰hŠîA˜a“cŽŠOA×ìK•vA‰iì‹IŽqA’†‘º‰pŽiAŽOŠ}Œ\‘¾A–ö¬–¾F ‰ºs‘å“®–¬‚ɑ΂·‚鎡—Ãí—ª
  19. ‘æ45‰ñ@“ú–{lH‘ŸŠíŠw‰ï‘å‰ïi2007”N10ŒŽ28-31“úF‘åãj
    ‹gìˆê—mA“cŽR‰hŠîA–x@‰pŽkAA“c’mGAÔ{WŽ¡A”ö“c@‹BA猴VŒáA•Ÿ‰iŽüŽiA–ö¬–¾F“ñ—t•Ù‚É‚æ‚éProsthetic valve dysfunction (PVD) ‚ÌŒŸ“¢
  20. ‘æ45‰ñ@“ú–{lH‘ŸŠíŠw‰ï‘å‰ïi2007”N10ŒŽ28-31“úF‘åãj
    H.Hori, S.Fukunaga, K.Yoshikawa, H.Akashi, S.AoyagiF Ten-year experience with the ATS open pivot bileaflet valves
  21. ‘æ69‰ñ@“ú–{—Õ°ŠO‰ÈˆãŠw‰ï‘‰ïi2007”N11ŒŽ28-12ŒŽ1“úF‰¡•lj
    ŽOŠ}Œ\‘¾AœA¼LˆêA‰iì‹IŽqA’†‘º‰pŽiA×ìK•vA˜a“cŽŠOA”ò‰i@ŠoA‹S’˽“ñA“c’†ŒúŽõA–¾Î‰prA–ö¬–¾F“–‰È‚É‚¨‚¯‚鉺Žˆ•ÂÇ«“®–¬d‰»Ç‚ɑ΂·‚錌ŠÇ“àŽ¡—Â̬Ñ
  22. ‘æ9‰ñ@¬læ“V«SŽ¾Š³Œ¤‹†‰ïi2007”N1ŒŽ13“úF“Œ‹žj
    Έ䎡‰ÀC{“cŒ›Ž¡CH“¡‰ÃŒöCˆÉ“¡WˆêC¼–ì@—TCâÄŽè“c—Y‰îCŠÝ–{T‘¾˜YC¼Î–LŽŸ˜YFƒy[ƒXƒ[ƒJ[Š³ŽÒ‚Ì”DP‚ÆoŽY Pregnancy and delivery in patients with pacemaker.
  23. ‘æ9‰ñ@¬læ“V«SŽ¾Š³Œ¤‹†‰ïi2007”N1ŒŽ13“úF“Œ‹žj
    Ô–Ø’õŽ¡C’†àV@½C’O‰HŒöˆê˜YCŽÂŒ´“¿ŽqC•P–ì˜a‰ÆŽqF¬læ“V«SŽ¾Š³‚̎Љï“I–â‘èG“Á‚É”DPEoŽY‚ÉŠÖ‚·‚é–â‘è“_ Social issues of about patients with congenital heart disease : Issues of pregnancy and delivery.
  24. ‘æ9‰ñ@¬læ“V«SŽ¾Š³Œ¤‹†‰ïi2007”N1ŒŽ13“úF“Œ‹žj
    Έ䎡‰ÀC{“cŒ›Ž¡C•P–ì˜a‰ÆŽqCâÄŽè“c—Y‰îCŠÝ–{T‘¾˜YCˆÉ“¡WˆêC¼–ì@—TC¼Î–LŽŸ˜YF•ª•ØEoŽY‚ðŒoŒ±‚µ‚½d“x‘å“®–¬•Ù‹·óŠ³ŽÒ‚Ì‚P—á Successful pregnancy and delivery in a patient with severe valvular aortic stenosis.
  25. ‘æ9‰ñ@¬læ“V«SŽ¾Š³Œ¤‹†‰ïi2007”N1ŒŽ13“úF“Œ‹žj
    Έ䎡‰ÀC{“cŒ›Ž¡CŠÝ–{T‘¾˜YCâÄŽè“c—Y‰îCˆÉ“¡WˆêC¼–ì@—TC¼Î–LŽŸ˜YF¬læ“V«SŽ¾Š³Š³ŽÒ‚ÌSˆö”½‰ž‚ÌŒŸ“¢ Psychogenic reaction in patients with cyanotic adult congenital heart disease.
  26. ‘æ18‰ñ“ú–{Pediatric Interventional CarsiologyŒ¤‹†‰ïi2007”N1ŒŽ19“úF•Ÿ‰ªj
    âÄŽè“c—Y‰îCŠÝ–{T‘¾˜YC¼–ì@—TCˆÉ“¡WˆêCΈ䎡‰ÀC‰Æ‘º‘fŽjC‘O–ì‘׎÷C {“cŒ›Ž¡D¼Î–LŽŸ˜YFƒRƒCƒ‹ÇðpŒã‚É”x‚ŒŒˆ³Ç‚Ì‘ˆ«‚ð”F‚ß‚½”x“®Ã–¬á‘‚Ì15Î’jŽ™—áD
  27. ‘æ18‰ñ“ú–{Pediatric Interventional CarsiologyŒ¤‹†‰ïi2007”N1ŒŽ19“úF•Ÿ‰ªj
    {“cŒ›Ž¡CH“¡‰ÃŒöC’I¬‰Ã•¶C‘O–ì‘׎÷CˆÀ‰i@OC‰Æ‘º‘fŽjCŠÝ–{T‘¾˜YCâÄŽè“c—Y‰îCΈ䎡‰ÀCˆÉ“¡WˆêC¼–ì@—TC¼Î–LŽŸ˜YFS–[’†ŠuŒ‡‘¹‚ɑ΂·‚éƒJƒe[ƒeƒ‹Ž¡—ÂƊO‰ÈŽ¡—Â̔äŠrD
  28. ‘æ18‰ñ“ú–{Pediatric Interventional CarsiologyŒ¤‹†‰ïi2007”N1ŒŽ19“úF•Ÿ‰ªj
    H“¡‰ÃŒöC{“cŒ›Ž¡C’I¬‰Ã•¶F‹É’[‚ɕΈʂµ‚½S–[’†Šu‚ɑ΂µ‚ÄCƒJƒe[ƒeƒ‹S–[’†ŠuŒ‡‘¹ì»p‚ðs‚Á‚½”x“®–¬•Â½Ç‚Ì1“ûŽ™—áD
  29. ‘æ18‰ñ“ú–{Pediatric Interventional CarsiologyŒ¤‹†‰ïi2007”N1ŒŽ19“úF•Ÿ‰ªj
    H“¡‰ÃŒöC{“cŒ›Ž¡C’I¬‰Ã•¶C‰Æ‘º‘fŽjCˆÉ“¡WˆêCΈ䎡‰ÀCâÄŽè“c—Y‰îCŠÝ–{T‘¾˜YC¼–ì@—TCŒj–Ø@½F“®–¬ŠÇƒRƒCƒ‹ÇðpŒã‚̶”xŒŒ—¬’ቺ‚Æ”x“®–¬“àƒRƒCƒ‹D
  30. ‘æ18‰ñ“ú–{Pediatric Interventional CarsiologyŒ¤‹†‰ïi2007”N1ŒŽ19“úF•Ÿ‰ªj
    ŠÝ–{T‘¾˜YC{“cŒ›Ž¡C¼–ì@—TCâÄŽè“c—Y‰îCˆÉ“¡WˆêCH“¡‰ÃŒöCΈ䎡‰ÀC]ãŒöNC›Œ´—mŽqC•P–ì˜a‰ÆŽqC‰Æ‘º‘fŽjC‘O–ì‘׎÷C¼Î–LŽŸ˜YC–ö¬–¾FŠ¥óÖ¬“´‚̉E–[‚Ö‚ÌŠJŒû•”•t‹ß‚ÖŒq‚ª‚銥“®–¬á‘‚ɑ΂·‚éƒRƒCƒ‹Çðp‚Ì1—áD
  31. ‘æ18‰ñ“ú–{Pediatric Interventional CarsiologyŒ¤‹†‰ïi2007”N1ŒŽ19“úF•Ÿ‰ªj
    Έä³_C–´“cLŽÀC–Ø‘ºƒlC’†”¨–í¶C‰Æ‘º‘fŽjC¬ìrˆêCˆ¼àV@‰qC’r“c‹v—YFìè•aŒãŠ¥“®–¬‹·ó•a•Ï‚ɑ΂·‚éƒJƒe[ƒeƒ‹Ž¡—Ẩ“ŠuŠú—\ŒãF‘½Ž{Ý‚É‚æ‚錟“¢D
  32. ‘æ13‰ñ@“ú–{‘ÙŽ™S‘Ÿ•aŒ¤‹†‰ïi2007”N2ŒŽ10“úF‹v—¯•Äj
    ‰º‘º’¼–çC‘ –{ãÄFC–ìX‰ºWŽqC‰iŽRË‘ãC—Ñ—´”V‰îC–x@‘å‘ CœA£²ŽqC‘O–ì‘׎÷C¼Î–LŽŸ˜YC‰Ã‘º•qŽ¡FŒŒŠÇ—Ö‚Ì‘ÙŽ™SƒGƒR[‚É‚æ‚éƒXƒNƒŠ[ƒjƒ“ƒOD
  33. ‘æ13‰ñ@“ú–{SIDSŠw‰ïŠwpW‰ïi2007”N3ŒŽ17“úF•Ÿ‰ªj
    ‘O–ì‘׎÷Fu“û—cŽ™“Ë‘RŽ€ÇŒóŒQ‚Ì”­¶Œ´ˆö‚Æ—\–h-—Þ‰Ž¾Š³CŽ–ŒÌŽ€‚â‹s‘Ò‚Æ‚ÌŠÓ•Ê‚àŠÜ‚ß‚Ä-v@“û—cŽ™‚ÌS‘Ÿ‚ÆSIDSD
  34. ‘æ444‰ñ@“ú–{¬Ž™‰ÈŠw‰ï•Ÿ‰ª’n•û‰ïi2007”N4ŒŽ7“úF•Ÿ‰ªj
    ˆäŽè‚ ‚₱CŠÝ–{T‘¾˜YC{“cŒ›Ž¡C¼–ì@—TCâÄŽè“c—Y‰îCΈ䎡‰ÀC‰Æ‘º‘fŽjC‘O–ì‘׎÷C¼Î–LŽŸ˜YD‰E‘å“®–¬‹|‚ðŒ_‹@‚Éf’f‚𓾂½ŒŒŠÇ—Ö‚Ì1V¶Ž™—áD
  35. ‘æ444‰ñ@“ú–{¬Ž™‰ÈŠw‰ï•Ÿ‰ª’n•û‰ïi2007”N4ŒŽ7“úF•Ÿ‰ªj
    H“¡‰ÃŒöC’I¬‰Ã•¶C{“cŒ›Ž¡C‰Æ‘º‘fŽjCΈ䎡‰ÀCˆÉ“¡WˆêCâÄŽè“c—Y‰îCŠÝ–{T‘¾˜YC¼–ì@—TC¼Î–LŽŸ˜YFAmplatzerS–[’†Šu•Â½ð‚ð—p‚¢‚½S–[’†ŠuŒ‡‘¹Ç•Â½p‚Ì“K‰žD
  36. ‘æ18‰ñ@“ú–{VƒGƒR[}Šw‰ïi2007”N4ŒŽ12“úFŒyˆä‘òj
    ‘O–ì‘׎÷CœA£²ŽqC•P–ì˜a‰ÆŽqC{“cŒ›Ž¡C¼Î–LŽŸ˜YD³í—á‚ÌE/A”äF‘ÙŽ™—̈æic’·SƒGƒR[}Šw‡TFLV torsion, E/A, Tei indexj
  37. ‘æ18‰ñ@“ú–{SƒGƒR[}Šw‰ïi2007”N4ŒŽ14“úFŒyˆä‘òj
    Έ䎡‰ÀC{“cŒ›Ž¡CH“¡‰ÃŒöC’rãVˆêC’I¬‰Ã•¶CâÄŽè“c—Y‰îCŠÝ–{T‘¾˜YCˆÉ“¡WˆêC¼–ì@—TC‰Æ‘º‘fŽjC‘O–ì‘׎÷C¼Î–LŽŸ˜YFŒoƒJƒe[ƒeƒ‹S–[’†ŠuŒ‡‘¹•Â½‘OŒã‚Ì‘gDƒhƒvƒ‰–@‚É‚æ‚é—¼S‹@”\•Ï‰»‚ÌŒŸ“¢D
  38. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    âÄŽè“c—Y‰îC{“cŒ›Ž¡CŠÝ–{T‘¾˜YC¼–ì@—TCˆÉ“¡WˆêCH“¡‰ÃŒöCΈ䎡‰ÀC‰Æ‘º‘fŽjC‘O–ì‘׎÷C¼Î–LŽŸ˜YFŠwZS‘ŸŒŸf‚Å”­Œ©‚³‚ꂽSë•””ì‘åŒ^S‹ØÇ‚Ì12Î’jŽ™—áD
  39. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    ‰Æ‘º‘fŽjC_“c@—mCŒF’J—D”üC“¡–ì@_C¼Î–LŽŸ˜YF¬Ž™‰Èˆã‚ð‚ǂ̂悤‚É‘‚₵‚Ä‚¢‚­‚© `ˆãŠw•”ˆê”N¶‚ɑ΂·‚éEarly exposure‚ÌŽŽ‚Ý`D
  40. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    ŠÝ–{T‘¾˜YC{“cŒ›Ž¡C“c’†—I•½CâÄŽè“c—Y‰îCΈ䎡‰ÀCH“cK‘åC‰Æ‘º‘fŽjC‘å•”ŒhŽOCŒÃ‰ê–õ•qC¼Î–LŽŸ˜YF‡¬rhAcidƒ¿Glucosidase•â[—Ö@‚ðs‚Á‚½Pomp•a‚Ì‚P“ûŽ™—áD
  41. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    Έ䎡‰ÀC‰Æ‘º‘fŽjCŠÝ–{T‘¾˜YCâÄŽè“c—Y‰îCˆÉ“¡WˆêC¼–ì@—TCH“¡‰ÃŒöC{“cŒ›Ž¡C’†‘ºDGC¼Î–LŽŸ˜YFŽ©ŠoÇó‚𔺂킸Ž‘±«SŽº•p”‚ªŠî–{’²—¥‚Æ‚È‚Á‚Ä‚¢‚½ˆê—áD
  42. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    ‘O–ì‘׎÷C‰ª“cƒˆê˜YC_ŒË‘¾˜YCœA£²ŽqC_“c@—mC“¡–ì@_C¼Î–LŽŸ˜YF ”DPŒãŠú‚Éf’f‚³‚ꂽ‘ÙŽ™•p”‚ÌŽüŽYŠúŠÇ—–@‚ÌŒŸ“¢F‘Ù“àŽ¡—Â̓K‰žD
  43. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    {“cŒ›Ž¡CH“¡‰ÃŒöC’I¬‰Ã•¶C‘O–ì‘׎÷C‰Æ‘º‘fŽjCΈ䎡‰ÀCŠÝ–{T‘¾˜YCâÄŽè“c—Y‰îCˆÉ“¡WˆêC¼Î–LŽŸ˜YFS–[’†ŠuŒ‡‘¹‚ɑ΂·‚éƒAƒ“ƒvƒ‰ƒbƒcƒA[•Â½ð‚ð—p‚¢‚½ƒJƒe[ƒeƒ‹Ž¡—ÂƊJSp‚Ì”äŠrD
  44. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    ‘O–ì‘׎÷CœA£²ŽqC•P–ì˜a‰ÆŽqCŠÝ–{T‘¾˜YCâÄŽè“c—Y‰îCΈ䎡‰ÀC‰Æ‘º‘fŽjC{“cŒ›Ž¡C‘è’¼Ž÷C¼Î–LŽŸ˜YF–³äBÇŒóŒQ‚Ì‘ÙŽ™f’f‚Æ—\Œã‚Ì„’è|”xÖ¬Œ`‘Ô‚Æ‹·ó|D
  45. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    {“cŒ›Ž¡CŠÝ–{T‘¾˜YCâÄŽè“c—Y‰îC¼–ì@—TCˆÉ“¡WˆêCH“¡‰ÃŒöCΈ䎡‰ÀC‰Æ‘º‘fŽjC¼Î–LŽŸ˜YFìè•aŠ³ŽÒƒÁƒOƒƒuƒŠƒ“•s‰ž—á‚ɑ΂·‚éD’†‹…ƒGƒ‰ƒXƒ^[ƒ[‘jŠQÜ(sivelestat sodium hydrate)‚ÌŒø‰ÊD
  46. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    –´“cLŽÀC{“cŒ›Ž¡CˆÉ“¡WˆêCâÄŽè“c—Y‰îCŠÝ–{T‘¾˜YCΈ䎡‰ÀC‰Æ‘º‘fŽjCΈä³_C㌴—¢’öC’†‘ºDˆêC¼Î–LŽŸ˜YFìè•a‘S‘’²¸‚Å•ñ‚³‚ꂽ‰‰ñŽ¡—ÃŒã‚Ì‚­‚·‚Ô‚èEÄ”R—á‚ÉŠÖ‚·‚錟“¢D
  47. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    Έ䎡‰ÀC{“cŒ›Ž¡CH“¡‰ÃŒöC’I¬‰Ã•¶CâÄŽè“c—Y‰îCŠÝ–{T‘¾˜YCˆÉ“¡WˆêC¼–ì@—TC‰Æ‘º‘fŽjC¼Î–LŽŸ˜YFŒoƒJƒe[ƒeƒ‹S–[’†ŠuŒ‡‘¹•Â½‘OŒã‚Ì—¼S‹@”\•Ï‰»‚Ì‘gDƒhƒvƒ‰–@‚É‚æ‚é•]‰¿D
  48. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    Έ䎡‰ÀC{“cŒ›Ž¡CˆÉ“¡WˆêCâÄŽè“c—Y‰îCŠÝ–{T‘¾˜YC¼–ì@—TCH“¡‰ÃŒöC‰Æ‘º‘fŽjC¼Î–LŽŸ˜YFŠ¥“®–¬•a•Ï‚ð‚à‚Âìè•aŠ³ŽÒ‚Ìèò“®–¬‚Ìelastic property‚ÌŒŸ“¢D
  49. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    H“¡‰ÃŒöD{“cŒ›Ž¡C’I¬‰Ã•¶CˆÀ‰i@OC‰|–{’¼ŽjC¼Î–LŽŸ˜YFƒtƒ@ƒ[Žl’¥pŒãŠ³ŽÒ‚Ìãs‘å“®–¬‚ÌŠg‘å‚Æelastic propertyD
  50. ‘æ110‰ñ@“ú–{¬Ž™‰ÈŠw‰ïi2007”N4ŒŽ21-22“úF‹ž“sj
    ŠÝ–{T‘¾˜YC{“cŒ›Ž¡CâÄŽè“c—Y‰îC¼–ì@—TCˆÉ“¡WˆêCΈ䎡‰ÀC‰Æ‘º‘fŽjCH“cK‘åCŒÃ‰ê–õ•qC¼Î–LŽŸ˜YFPompe•a‚ɑ΂·‚釬y‘f•â[—Ö@‚ðs‚¢2ŽŸ«S‹ØÇ‚ÆœŠi‹Ø‹@”\‚̉ü‘P‚𓾂½1“ûŽ™—áD
  51. ‘æ80‰ñ@“ú–{’´‰¹”gˆãŠw‰ïŠwpW‰ïi2007”N5ŒŽ18-20“úFŽ­Ž™“‡j
    ‘O–ì‘׎÷F¬Ž™‰ÈEŽY•wl‰È@”DP’†Šú‚Ì‘ÙŽ™ˆÙí‚̃XƒNƒŠ[ƒjƒ“ƒO@zŠÂŠí•ª–ì‚̃XƒNƒŠ[ƒjƒ“ƒO
  52. ‘æ43‰ñ@“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïi2007”N7ŒŽ8-10“úF“Œ‹žj
    œA£²ŽqC_ŒË‘¾˜YC_“c@—mC“¡–ì@_C‘O–ì‘׎÷C‘ –{ºFC–x@‘å‘ C‰Ã‘º•qŽ¡C¼Î–LŽŸ˜YF‘ÙŽ™f’f‚µŽüŽYŠúŠÇ—‚ðs‚Á‚½•Ð‘¤”xÖ¬‚ÉdÇ‹·ó‚𔺂¤–³äBÇŒóŒQ‚Ì2Ç—áD
  53. ‘æ39‰ñ@“ú–{ˆãŠw‹³ˆçi2007”N7ŒŽ27-28“úF·‰ªj
    ‰Æ‘º‘fŽjC¼‰º—D”üC“¡–ì@_C‹g‰i—zˆê˜YC–{ŠÔ^ˆêC]Œût•FCˆä㌪‹gC“ú‹g•Û•FC“c’†’n•½C•’J@–ÎC¼Î–LŽ¡˜YF¬Ž™‰ÈƒNƒŠƒjƒbƒNŽÀK‚ðƒNƒŠƒjƒJƒ‹ƒNƒ‰[ƒNƒVƒbƒv‚É“±“ü‚µ‚Ä`“±“üŒã5”N‚Ì‚Ü‚Æ‚ß`
  54. ‘æ17‰ñ@“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ïi2007”N8ŒŽ26“úFŒF–{j
    –´“cLŽÀF‹Ö‰ŒE–h‰ŒŽ‘—¿‚­‚è‚̃mƒEƒnƒED
  55. ‘æ11‰ñ@ìè•aŽ¡—ç˜b‰ïi2007”N9ŒŽ15“úF‘åãj
    –´“cLŽÀDìè•aŠ¥“®–¬•a•Ï‚ւ̃Jƒe[ƒeƒ‹Ž¡—Ëy‚ÑŠO‰È“IŽ¡—Ẩ“ŠuŠú—\ŒãD
  56. ‘æ27‰ñ@“ú–{ìè•aŒ¤‹†‰ïi2007”N10ŒŽ11-12“úF“Œ‹žj
    ˆÉ“¡WˆêC{“cŒ›Ž¡CŠÝ–{T‘¾˜YCâÄŽè“c—Y‰îCH“¡‰ÃŒöCΈ䎡‰ÀC‰Æ‘º‘fŽjC¼Î–LŽŸ˜YFìè•a‹¹…’™—¯‚ð‡•¹‚µ‚½2Ç—áDTwo cases of Kawasaki disease with Pleural effusion.
  57. ‘æ27‰ñ@“ú–{ìè•aŒ¤‹†‰ïi2007”N10ŒŽ11-12“úF“Œ‹žj
    –´“cLŽÀC{“cŒ›Ž¡CˆÉ“¡WˆêCΈ䎡‰ÀC‰Æ‘º‘fŽjCΈä³_C’†‘ºDˆê: ìè•aŠ³ŽÒ‚͂ǂ̂悤‚ÉŽóf‚µCŽ¡—ÂðŽó‚¯‚Ä‚¢‚é‚©H|‘æ18‰ñ‘S‘’²¸¬Ñ‚ð—p‚¢‚½ŒŸ“¢|DHow patients with Kawasaki disease consult the doctor and receive treatment? -From the analysis of 18th nationwide survey in Japan-.
  58. ‘æ27‰ñ@“ú–{ìè•aŒ¤‹†‰ïi2007”N10ŒŽ11-12“úF“Œ‹žj
    Έ䎡‰ÀC{“cŒ›Ž¡C¼–ì@—TCâÄŽè“c—Y‰îCŠÝ–{T‘¾˜YCˆÉ“¡WˆêC‰Æ‘º‘fŽjC¼Î–LŽŸ˜YF‘ŠO‚É‚Ä”­Ç‚µCìè•a‚Æf’fEŽ¡—³‚ê,‹‘劥“®–¬áŽ‚ðŒ`¬‚µ‚½1—áD
  59. ‘æ27‰ñ@“ú–{ìè•aŒ¤‹†‰ïi2007”N10ŒŽ11-12“úF“Œ‹žj
    ]ãŒöNCâÄŽè“c—Y‰îCŠâŒ³“ñ˜YC–´“cLŽÀC{“cŒ›Ž¡: ìè•aŽ¡—Âɂ¨‚¯‚é–ƉuƒOƒƒuƒŠƒ“2g/kg’P‰ñ“Š—^Œã‚Ì•s‰ž—á‚ÉŠÖ‚·‚錟“¢F”­”M‚Æ”»’f‚·‚é‘̉·‚Æ‚»‚Ì”»’莞Šú‚ɂ‚¢‚ÄDThe examination concerning the non-responder after IVIG 2g/kg in the Kawasaki disease treatment : About fever and judgement of temperature and time.
  60. ‘æ27‰ñ@“ú–{ìè•aŒ¤‹†‰ïi2007”N10ŒŽ11-12“úF“Œ‹žj
    âÄŽè“c—Y‰îC{“cŒ›Ž¡CŠÝ–{T‘¾˜YCˆÉ“¡WˆêCΈ䎡‰ÀC‰Æ‘º‘fŽjCH“¡‰ÃŒöC]ãŒöNCŠâŒ³“ñ˜YC¼Î–LŽŸ˜Y:ƒÁƒOƒƒuƒŠƒ“•s‰ž‚Ììè•a‚ɑ΂·‚éƒXƒeƒƒCƒhƒpƒ‹ƒX—Ö@‚ÌŒŸ“¢DSreroid Pulse Therapy as the 2nd Treatment of Gamma Globurin in Kawasaki syndrome.
  61. ‘æ27‰ñ@“ú–{¬Ž™zŠÂ“®‘ÔŒ¤‹†‰ï(2007”N10ŒŽ20“úF‘åãj
    Έ䎡‰ÀD–³Çó‚ÌS‘©Œ^S‹ØÇ1Ç—á‚ÌŒŸ“¢D
  62. ‘æ28‰ñ@“ú–{ƒAƒtƒFƒŒ[ƒVƒXŠw‰ïi2007”N11ŒŽ16-18“úF‹v—¯•Äj
    Έ䎡‰ÀD‘ŠO‚É‚Ä”­Ç‚µCìè•a‚Æf’fEŽ¡—³‚êC‹‘劥“®–¬áŽ‚ðŒ`¬‚µŒŒŸ÷ŒðŠ·‚ðŽ{s‚µ‚½‚PÇ—áD
  63. ‘æ52‰ñ@“ú–{–¢nŽ™V¶Ž™Šw‰ïi2007”N11ŒŽ24-26“úF‚¼j
    ‘O–ì‘׎÷CœA£²ŽqC_ŒË‘¾˜YC_“c@—mC“¡–ì@_C–x@‘å‘ C¼Î–LŽŸ˜YFSŽº’†ŠuŒ‡‘¹Ç‚Ìo¶‘Of’f‚ÆŽüŽYŠúŠÇ—D
  64. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Roundtable Discussion 4 'Clinical Evaluation and Application of Endothelial Function' Matsuoka H, Imagism T: Assessment of endothelial function by flow-mediated vasodilatation using ultrasonography.
  65. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Featured Research Session 20 Enomoto M, Adachi H, Furuki K, Kumagae S, Otsuka M, Shigetoh Y, Fukami A, Satoh A, Imagism T: High serum dehydroepiandrosteone sulfate levels are strikingly associated with less mortality in men. (27-year follow-up study) ˆê”ʉ‰‘è
  66. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Arima K, Katsuda Y, Saitoh Y, Katsuki Y, Sasaki K, Yamagishi S, Ikeda H, Kai H, Imagism T: Inhibition of anti-angiogenic factor, pigment epithelium-derived factor, improves ischemic angiogenesis in klotho mice.
  67. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Arima K, Katsuda Y, Saitoh Y, Katsuki Y, Sasaki K, Yamagishi S, Ikeda H, Kai H, Imagism T: Role of anti-angiogenic factor, pigment epithelium-derived factor, in VEGF-induced angiogenesis in klotho mice.
  68. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Enomoto M, Adachi H, Furuki K, Kumagae S, Otsuka M, Shigetoh Y, Fukami A, Satoh A, Imagism T: Impact of higher blood pressure on the risk of death in 27-year follow-up study.
  69. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Ohmura H, Oka N, Miyazaki H, Ueda T, Imagism T: Roles of lysyl oxidase-like protein in heart.
  70. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Katsuki Y, Sasaki K, Katsuda Y, Toyama Y, Imagism T: Neovascularization capacity of endothelial progenitor cells (EPC) in patients with Buerger's disease.
  71. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Katsuda Y, Saitoh Y, Arima K, Katsuki Y, Toyama Y, Sasaki K, Ikeda H, Imagism T: Occlusion level of limb artery predicts the efficacy of bone marrow mononuclear cell implantation for critical limb ischemia.
  72. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Kumagae S, Adachi H, Enomoto M, Fukami A, Satoh A, Shigetoh Y, Otsuka M, Furuki K, Imaizumi T: TGF-ƒÀ1 is a marker for left ventricular hypertrophy in hypertensive subjects in a general population. Saitoh Y, Sasaki K, Katsuda Y, Murohara T, Takeshita Y, Okazaki T, Arima K, Katsuki Y, Shintani S, Shimada H, Akashi H, Ikeda H, Imaizumi T: Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease.
  73. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Satoh S, Mori E, Yokoyama S, Kimura Y, Sugihara M, Ikeda S, Nakayama S, Ikeda J, Morii S, Esaki E, Aso A, Nakamura T, Matsumoto T, Hiyamuta K: Different of inflammatory markes and lymphocyte subsets at the culprit lesions between patient with stable angina and acute coronary syndromes.
  74. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Shigetoh Y, Adachi H, Enomoto M, Satoh A, Fukami A, Kumagae S, Otsuka M, Furuki K, Imaizumi T: Heart rate is a predictor for development of abnormal glucose metabolism: Prospective study for 20 years in a general population.
  75. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Jinnouchi Y, Yamagishi S, Nakamura K, Takenaka K, Ueda S, Imaizumi T: Pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice.
  76. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Sugi Y, Yasukawa H, Kai H, Fukui D, Futamata N, Koga M, Imaizumi T: Circulating dendritic cells numbers are associated with cardiac injury and prognosis in patients with decompensated heart failure.
  77. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Takayama N, Kai H, Kudoh H, Sugi Y, Fukui D, Takemiya K, Ikeda A, Yasukawa H, Imaizumi T: Effect of simvastatin and telmiartan on hypertensive cardiac remodeling by exaggerated blood pressure variability in spontaneously hypertensive rats.
  78. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Takenaka K, Yamagishi S, Nakamura K, Jinnouchi Y, Ueda S, Imaizumi T: Pigment epithelium-derived factor (PEDF) inhibits occlusive thrombus formation: Possible participation of reduced intraplatelet PEDF levels in acute coronary syndromes.
  79. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Takemiya K, Kai H, Takayama N, Mori T, Kudoh H, Ikeda A, Sugi Y, Fukui D, Futamata N, Tahara N, Yasukawa H, Imaizumi T: Mesenchymal stem cell-transplantation improves endothelial function in monocrotaline-induced pulmonary hypertension rats.
  80. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Tahara N, Mizoguchi M, Mizuta Y, Osada K, Ishibashi M, Yamagishi S, Imaizumi T: Efficacy of fasting 18F-fluorodeoxyglucose positron emission tomography for the detection of cardiac sarcoidosis.
  81. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Nakamura K, Imaizumi T, Adachi H, Jinnouchi Y, Yamagishi S, Ueda S, Takenaka K: Pigment epithelium-derived factor (PEDF) inhibits neointima formation by suppressing NADPH oxidase-mediated reactive oxygen speciesgeneration.
  82. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Fukami A, Adachi H, Furuki K, Kumagae S, Otsuka M, Shigetoh Y, Satoh A, Enomoto M, Imaizumi T: The association between serum monocyte chemoattractant protein-1 (MCP-1) and the metabolic syndrome.
  83. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Futamata N, Yasukawa H, Koga M, Fukui D, Sugi Y, Kai H, Imaizumi T: Simvastatin suppresses dendritic cell-induced autoimmune myocarditis via inhibition of dendritic cell activation.
  84. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Furuki K, Adachi H, Enomoto M, Satoh A, Fukami A, Kumagae S, Otsuka M, Matsuoka H, Ikeda H, Koga Y, Imaizumi T: Elevated plasma levels of asymmetric dimethylarginine (ADMA) and homocysteine (Hcy) are strongly associated with carotid atherosclerosis: An epidemiological study.
  85. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Matsumoto Y, Ueda S, Yamagishi S, Matsuoka H, Imaizumi T, Okuda S: Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis.
  86. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Mizuta Y, Kai H, Tahara N, Osada K, Fukui M, Imaizumi T: Valsartan attenuated myocardial fibrosis and diastolic dysfunction of hypertensive hypertrophied hearts in humans. Assessments using integrated backscatter analysis.
  87. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Mizoguchi M, Tahara N, Yamagishi S, Mizuta Y, Osada K, Ishibashi M, Imaizumi T: The disparity in the determinant factors between atherosclerosis and vascular inflammation.
  88. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Mori T, Kai H, Kudo H, Sugi Y, Takayama N, Fukui D, Ikeda A, Koga M, Yasukawa H, Imaizumi T: Prolonged enhancement of perivascular inflammation and oxidative stress aggravates hypertensive myocardial fibrosis and diastolic dysfunction in ovariectomized rats.
  89. ‘æ71‰ñ@“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15?17“úF_ŒËj
    Yamamoto T, Yasukawa H, Koga M, Sugi Y, Fukui D, Futamata N, Kai H, Hoshijima M, Kataoka Y, Imaizumi T: Lacking the SOCS3 gene in macrophages prevents the development of atherosclerosis in ApoE deficient mice.
  90. ‘æ32‰ñ@“ú–{”]‘²’†Šw‰ïŠwpW‰ïi2007”N3ŒŽ22?24“úF•Ÿ‰ªj
    ‡“¯ƒVƒ“ƒ|ƒWƒEƒ€‚Q "”]‘²’†‚̃Cƒ[ƒWƒ“ƒOFƒ}ƒNƒ‚©‚çƒ~ƒNƒ‚Ü‚Å" b”ã‹vŽjA“cŒ´éLA¡ò •×F“®–¬d‰»ƒvƒ‰[ƒNŠˆ“®«‚ðFDG-PET‚Å•]‰¿‚µ‚¤‚é‚©iµ‘Òj
  91. ‘æ104‰ñ@“ú–{“à‰ÈŠw‰ïu‰‰‰ïi2007”N4ŒŽ3`5“úF‘åãj
    ‰|–{”ü‰ÀA‘«’B@ŽõA²“¡@WA[…ˆŸŽqA‘å’Ë–ƒŽ÷AŒF’JrˆêAŒÃ–Ø‹v”üŽqA¡ò@•×FŒŒ’†DHEAS’l‚Í’j«‚É‚¨‚¯‚é’·Žõ‚Ì—\’mˆöŽq‚Å‚ ‚é\27”N‚ɂ킽‚é’·Šú‘OŒü‚«Œ¤‹†‚©‚ç\
  92. ‘æ80‰ñ@“ú–{ŽY‹Æ‰q¶Šw‰ïŠwpW‰ïi2007”N4ŒŽ25?28“úF‘åãj
    –L‘Œ÷ŽŸA‰Á“¡’‰•FFŒ¤Cˆã‚Ì1”NŒã‚̃ƒ“ƒ^ƒ‹ƒwƒ‹ƒX‚É‹y‚Ú‚·ŠÖ˜A—vˆö‚ÌŒŸ“¢
  93. ‘æ277‰ñ@“ú–{“à‰ÈŠw‰ï‹ãB’n•û‰ïi2007”N5ŒŽ12“úF²‰êj
    –ƒ¶–¾Œ©A’†‘ºr”ŽA’r“cŽŸ˜YA–Ø‘ºD–MA‰¡ŽRW“ñAX@’´•vA²“¡^ŽiA¼–{‚GA—â–´“c_ŽiF”­ì«ãŽº«•p”Ç‚ð‡•¹‚µ‚½‚“x–[ŽºƒuƒƒbƒN‚ɑ΂µƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ƃy[ƒXƒ[ƒJ[Až‚Ýp‚ðs‚Á‚½ˆê—á
  94. ‘æ50‰ñ@“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ïi2007”N5ŒŽ24?26“úFå‘äj
    w“à—TŽqAŽRŠÝ¹ˆêA’†‘º˜a¶A’|’†Ž•FAA“cWˆê˜YA¼ˆäFŒ›A’|’†³‹`A¡ò@•×FƒAƒgƒ‹ƒoƒXƒ^ƒ`ƒ“‚ÍA2Œ^“œ”A•aŠ³ŽÒ‚É‚¨‚¯‚錌’†AGEsƒŒƒxƒ‹‚ð’ቺ‚³‚¹‚é
  95. ‘æ50‰ñ@“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ïi2007”N5ŒŽ24?26“úFå‘äj
    ’|’†Ž•FAŽRŠÝ¹ˆêA’†‘º˜a¶Aw“à—TŽqAA“cWˆê˜YA¼ˆäFŒ›A’|’†³‹`A¡ò@•×FŒŒ´‰Â—nŒ^RAGE‚ÆAGEsƒŒƒxƒ‹‚ͳ‘ŠŠÖ‚·‚é
  96. ‘æ22‰ñ@“ú–{•s®–¬Šw‰ïŠwp‘å‰ï (2007”N5ŒŽ31“ú`6ŒŽ2“úFL“‡)
    –ƒ¶–¾Œ©A’†‘ºr”ŽA—â–´“c_ŽiFŠO‰È“I‚ÉS“à–ŒƒŠ[ƒh”²‹Žp‚ð•K—v‚Æ‚µ‚½ƒy[ƒXƒ[ƒJ[Až‚ÝpŒã‚Ì“ñÇ—á
  97. ‘æ22‰ñ@“ú–{•s®–¬Šw‰ïŠwp‘å‰ï (2007”N5ŒŽ31“ú`6ŒŽ2“úFL“‡)
    Œ “¡Œ’Ž÷A‹g“c‹P‹vAˆî–Ñ’qmA’|“à’qGA‰iŒ³NŽkA•Ÿ“c—TŽŸ˜YA¡ò •×F‚“x‹~‹}‹~–½ƒZƒ“ƒ^[‚Ö”À“ü‚³‚ꂽ–òÜ«dÇÕs®–¬‚ɂ‚¢‚Ä‚ÌŒŸ“¢ Ž‡Œ´”ü˜aŽqA•½–Ø’B˜NFˆÙ‚È‚é‹@˜‚ÉŠî‚­S–[•p”‚ɑ΂·‚éNon-contact mapping‚ð—p‚¢‚½ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“p
  98. ‘æ22‰ñ@“ú–{•s®–¬Šw‰ïŠwp‘å‰ï (2007”N5ŒŽ31“ú`6ŒŽ2“úFL“‡)
    ’|“à’qGA‹g“c‹P‹vAˆî–Ñ’qmAŒ “¡Œ’Ž÷A•Ÿ“c—TŽŸ˜YA‰iŒ³NŽkA¡ò •×F–òÜŽ¡—Ã’ïR«‚Ì‹N—§«’ጌˆ³‚ɑ΂·‚éV‚½‚ÉŠJ”­‚³‚ꂽƒy[ƒVƒ“ƒOƒAƒ‹ƒSƒŠƒYƒ€‚ð—p‚¢Ž¡—ÂɬŒ÷‚µ‚½1—á
  99. ‘æ16‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2007”N6ŒŽ21`23“úFŒSŽRj
    Katsuda Y, Kanaya S, Koiwaya H, Ootsuka M, Toyama Y, Arima K, Katsuki Y, Onitsuka I, Sasaki K, Takajo Y, Kai HF Early and long-term outcome of small stent: Drug eluting stent vs. Bare metal stent.
  100. ‘æ16‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2007”N6ŒŽ21`23“úFŒSŽRj
    Satoh S, Mori E, Yokoyama S, Kimura Y, Esaki E, Sugihara M, Nakayama S, Ikeda J, Morii S, Ikeda S, Matsumoto T, Hiyamuta K: Relationship study between coronary plaque composition and local atherogenic mediators in patients with stable angina using ultrasound radiofrequency data analysis.
  101. ‘æ16‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2007”N6ŒŽ21`23“úFŒSŽRj
    Yokoyama S, Mori E, Kimura Y, Sugihara M, Nakayama S, Nakamura T, Satoh S, Matsumoto T, Hiyamuta K: Clinacal outcome of sirolimus eluting stent implantation for left main trunk disease.
  102. ‘æ102‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N6ŒŽ23“úF‹{èj
    –ƒ¶–¾Œ©A’†‘ºr”ŽAˆä㊰ŽqA´…’m•FA’r“cŽŸ˜YAXˆä½ŽmA’r“c^‰îA–Ø‘ºD–MA‰¡ŽRW“ñAX@’´•vA²“¡^ŽiA¼–{‚GA—â–´“c_ŽiFŽ¸_‚ðŽå‘i‚Æ‚µ‚½”­ì«ãŽº«•p”Ç
  103. ‘æ102‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N6ŒŽ23“úF‹{èj
    ˆä㊰ŽqA²“¡^ŽiA™Œ´@[A]è‰pŽiA’†ŽR@GA´…’m•FA’r“cŽŸ˜YAXˆä½ŽmA’r“c^‰îA–ƒ¶–¾Œ©A–Ø‘ºD–MA‰¡ŽRW“ñAX@’´•vA’†‘ºr”ŽA¼–{‚GA—â–´“c_ŽiF“–‰@‚É‚¨‚¯‚é‹}«S‹Ø[ÇŒãS”j—ôÇ—á‚Ì—Õ°“I”wŒi‚ÌŒŸ“¢
  104. ‘æ102‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N6ŒŽ23“úF‹{èj
    ‰Y•”‘ŽqA‚éŠì“TA²X–ØŒ’ˆê˜YA”~ˆäG˜aA²“¡@WAÄ“¡@—TA•ûŒ¦‰ÌA”‰ƒ¼Ž÷Ab”ã‹vŽjA¡ò@•×F–UŒŸ‚ʼn󎀫DŽ_‹…«S‹Ø‰Š‚ª”»–¾‚µ‚½ˆê—á
  105. ‘æ102‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N6ŒŽ23“úF‹{èj
    ]è‰pŽiAŠâèŒc”üA²“¡^ŽiA™Œ´@[A’†ŽR@GA–ƒ¶–¾Œ©A’r“cŽŸ˜YAXˆä½ŽmA’r“c^‰îA–Ø‘ºD–MA‰¡ŽRW“ñAX@’´•vA¼–{‚GA’†‘ºr”ŽA—â–´“c_ŽiFS‹Øˆí’Ey‘f‚Ì㸂ð”F‚ß‚È‚©‚Á‚½DŽ_‹…‘‘½Ç‚É”º‚¤LoefflerS‹Ø‰ŠES–Œ‰Š‚Ì1—á
  106. ‘æ102‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N6ŒŽ23“úF‹{èj
    •ûŒ¦‰ÌA“cŒ´éLAaŒûƒ~ƒmƒŠA”~ˆäG˜aA²X–ØŒ’ˆê˜YA‚éŠì“TA‰Y•”‘ŽqA™@—Y‰îAH“¡”ŽŽiAb”ã‹vŽjA¡ò@•×FŽíX‚Ì”x“®–¬«‚ŒŒˆ³Ç‚ɑ΂·‚éƒGƒ“ƒhƒZƒŠƒ“hR–ò‚Ì–«Œø‰Ê
  107. ‘æ102‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N6ŒŽ23“úF‹{èj
    Ž™‹Ê‹I—mA‚éŠì“TA²X–ØŒ’ˆê˜YA”~ˆäG˜aA•‹{´ŽqA‹à’J½ŽiAb”ã‹vŽjA ¡ò@•×A‰Á“¡½–çF‹}‘¬‚ÉŽlŽˆ––’[‰óŽ€‚𗈂½‚µ‚½”畆Œ^‘½”­Œ‹ß«“®–¬‰Š‚Æl‚¦‚ç‚ê‚éˆê—á
  108. ‘æ102‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N6ŒŽ23“úF‹{èj
    Ž‡Œ´”ü˜aŽqA“잊‘׋PA‘ëˆä‰pˆêAŒÃ‰êͳA•½–Ø’B˜NFNon-contact mapping‚ð—p‚¢‚Ä‚RŽí—Þ‚Ì㎺«•p”‚̃Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ɬŒ÷‚µ‚½‚P—á
  109. ‘æ7‰ñ@“ú–{R‰Á—îˆãŠw‰ï‘‰ïi2007”N7ŒŽ20`21“úF‹ž“sj
    ‰|–{”ü‰ÀA‘«’B@ŽõA[…ˆŸŽqAŒF’JrˆêA¡ò@•×FŒŒ´DHEAS‚’l‚Í’j«‚Å‚Í’·Žõ‚Ì—\’mˆöŽq‚Å‚ ‚éA\27”NŠÔ‚̉uŠw“IŒŸ“¢\
  110. ‘æ7‰ñ@“ú–{SŒŒŠÇƒJƒe[ƒeƒ‹Ž¡—Êw‰ïŠwpW‰ï (2007”N8ŒŽ2?4“úF–¼ŒÃ‰®)
    Katsuki Y, Katsuda Y, Kanaya S, Ohtsuka M, Koiwaya H, Toyama Y, Arima K, Onitsuka I, Sasaki K, Takajo Y, Kai H, Imaizumi T: Long-term outcome of small stent: Sirolimus eluting stent vs Bare metal stent.
  111. ‘æ278‰ñ@“ú–{“à‰ÈŠw‰ï‹ãB’n•û‰ïi2007”N 8ŒŽ18“úF‹v—¯•Äj
    –ؗTŽiAˆî–Ñ’qmA‹S’ˈê˜YA™@—Y‰îAˆä¯²’mŽqAŒÃ‘‘ •¶AˆÀ‰ª ˆíAw“à—TŽqAb”ã‹vŽjA¡ò •×FdÇMRSAS“à–Œ‰Š‚ɑ΂µƒy[ƒXƒ[ƒJ[ƒŠ[ƒh‚Ì”²‹Ž‚ª‘tŒø‚µ‚½ˆê—á
  112. ‘æ278‰ñ@“ú–{“à‰ÈŠw‰ï‹ãB’n•û‰ïi2007”N 8ŒŽ18“úF‹v—¯•Äj
    ˆä¯²’mŽqA‹S’ˈê˜YAˆî–Ñ’qmA™@—Y‰îA“cŒ´éLA’|’†Ž•FAŠâŒ³”üŽqAV“c—ǘaAb”ã‹vŽjA¡ò@•×F––’[”ì‘åÇ‚É‘å“®–¬•Ù•Â½•s‘S‚ð‡•¹‚µ‚½ˆêÇ—á
  113. ‘æ4‰ñ@“ú–{SŒŒŠÇƒJƒe[ƒeƒ‹Ž¡—Êw‰ï‹ãB’n•û‰ïA‘æ14‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ï‹ãB’n•û‰ï•½¬19”N“x‹ãB‡“¯’n•û‰ïi2007”N8ŒŽ24`25“úFŒF–{j
    ˆä㊰ŽqAX@’´•vA´…’m•FA’r“cŽŸ˜YAXˆä½ŽmA’‡‹gF°A™Œ´@[A“c’†M‰pA–ƒ¶–¾Œ©AX@—²GA–Ø‘ºD–MA‰¡ŽRW“ñA’†‘ºr”ŽA²“¡^ŽiA—â–´“c_ŽiF”牺A‚¦ž‚ÝŒ^ˆêŽž“I‰º‘åÖ¬ƒtƒBƒ‹ƒ^[‚ð—p‚¢‚½[•”Ö¬ŒŒðÇA”x“®–¬ŒŒðÇðǂɑ΂·‚é‘Šú—£°‚ÌŽŽ‚Ý
  114. ‘æ4‰ñ@“ú–{SŒŒŠÇƒJƒe[ƒeƒ‹Ž¡—Êw‰ï‹ãB’n•û‰ïA‘æ14‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ï‹ãB’n•û‰ï•½¬19”N“x‹ãB‡“¯’n•û‰ïi2007”N8ŒŽ24`25“úFŒF–{j
    ’|’†Ž•FAŸ“c—m•ãAŠOŽRN”VAŒŽ—^Žu•vA²X–ØŒ’ˆê˜YA‹à’J½ŽiA‹S’ˈê˜YA‰i“c@„A‚éŠì“TAb”ã‹vŽjA¡ò@•×F––½•ÛŒìƒfƒBƒoƒCƒXiFiltrapj‚̉ñŽû‚ª¢“ï‚Å‚ ‚Á‚½ˆê—á
  115. ‘æ17‰ñ@“ú–{”A˜HŒ‹ÎÇŠw‰ïŠwpW‰ïi2007”N8ŒŽ25“úF‹v—¯•Äj
    ¡ò@•×FŽ_‰»ƒXƒgƒŒƒX‚ÍŒŒŠÇi”AŠÇHj“à”çŠQ‚ð‚«‚½‚µŒŒŠÇi”AŠÇHj‚ð‹l‚܂点‚é
  116. ‘æ11‰ñ@“ú–{S•s‘SŠw‰ïŠwpW‰ïi2007”N9ŒŽ9?10“úF‰YˆÀj
    Symposium7 'Therapeutic Approach to Acute Heart Failure' Ohuchida M, Imaizumi T: The therapeutic strategy for acute heart failure: From the view point of renal protection.
  117. ‘æ11‰ñ@“ú–{S•s‘SŠw‰ïŠwpW‰ïi2007”N9ŒŽ9?10“úF‰YˆÀj
    Inage T, Yoshida T, Takeuchi T, Nagamoto Y, Gondo T, Fukuda Y, Imaizumi T: Chronic cardiac resynchronization therapy reverses cardiac remodeling and improves invasive hemodynamics of patients with severe heart failure on optimal medical treatment.
  118. ‘æ11‰ñ@“ú–{S•s‘SŠw‰ïŠwpW‰ïi2007”N9ŒŽ9?10“úF‰YˆÀj
    Takayama N, Kai H, Kudo H, Mori T, Sugi Y, Fukui D, Takemiya K, Ikeda A, Yasukawa H, Imaizumi T: Simvastatin attenuates the large blood pressure variability-induced cardiac hypertrophy by inhibiting ERK and Rho A.
  119. ‘æ11‰ñ@“ú–{S•s‘SŠw‰ïŠwpW‰ïi2007”N9ŒŽ9?10“úF‰YˆÀj
    Mori T, Kai H, Kudo H, Takemiya K, Takayama N, Imaizumi T: Estradiol improves hypertensive myocardial fibrosis and diastolic dysfunction in ovariectomized rats by attenuating inflammatory changes.
  120. ‘æ11‰ñ@“ú–{S•s‘SŠw‰ïŠwpW‰ïi2007”N9ŒŽ9?10“úF‰YˆÀj
    Yasukawa H, Sugi Y, Kai H, Imaizumi T: Numbers of circulating dendritic cells are associated with cardiac injury and prognosis in patients with decompensated heart failure.
  121. ‘æ45‰ñ@‘S‘‘åŠw•ÛŒ’ŠÇ—Œ¤‹†W‰ïi2007”N10ŒŽ10?11“úF‘啪j
    –L‘Œ÷ŽŸA‰ÍŒ´“cN‹MF—Žq‘åŠw¶‚É‚¨‚¯‚éÁ‰»ŠÇQOL•s’²‚Æ‚»‚ÌŠÖ˜A—vˆö‚ɂ‚¢‚Ä
  122. ‘æ45‰ñ@“ú–{“œ”A•aŠw‰ï‹ãB’n•û‰ïi2007”N10ŒŽ12`13“úF‹{èj
    ‹´‰ir•FA¬“c•ÓCˆêA˜a“c’¨•FA•Ÿ’J’mAŒ´@‹ÅgAœA“c—LrA’†ŽR‚ЂƂÝA™@Œ’ŽOA’r“c‹v—YAŽR“cŒ¤‘¾˜YFƒEƒGƒXƒgŽüˆÍŒa‚Æ“à‘ŸŽ‰–b–ÊÏ‚Æ‚ÌŠÖ˜A‚É‚¨‚¯‚é«·‚ÌŒŸ“¢
  123. ‘æ48‰ñ@“ú–{–¬ŠÇŠw‰ï‘‰ïi2007”N10ŒŽ25“úF¼–{j
    JCAƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[‚P"ŒŒŠÇ“à”ç‹@”\•]‰¿‚Ì•W€‰»‚Ö‚ÌŽŽ‚Ý" ¼‰ªG—mFŒŒŠÇ“à”ç‹@”\•]‰¿‚Ì—Õ°‰ž—pFFMDŒŸ¸‚Ì•W€‰»
  124. ‘æ30‰ñ@“ú–{‚ŒŒˆ³Šw‰ïŠwpW‰ïi2007”N10ŒŽ25?27“úF‹X–ì˜pj
    ’r“c—–]Ab”ã‹vŽjAX@—²GA‚ŽR¬­AH“¡”ŽŽiAˆÀ‰ª@ˆíA¡ò@•×F•ÂŒoŒã‚ŒŒˆ³«”ì‘åSƒ‚ƒfƒ‹‚É‚¨‚¯‚éŠg’£áŠQ‚Ì‹@˜-E‚QŒ‡–R‚É‚æ‚éS‹Ø“àŒŒŠÇŽüˆÍ‰ŠÇ‚ÆS‹ØüˆÛ‰»‚Ì‘ˆ«-
  125. ‘æ30‰ñ@“ú–{‚ŒŒˆ³Šw‰ïŠwpW‰ïi2007”N10ŒŽ25?27“úF‹X–ì˜pj
    ‰|–{”ü‰ÀA‘«’B@ŽõA²“¡@WA[…ˆŸŽqA‘å’Ë–ƒŽ÷AŒF’JrˆêAŒÃ–Ø‹v”üŽqA“잊‘׋PA¡ò@•×F‘SŽ€–S‚ɂǂ̉ŠÇƒ}[ƒJ[‚ª—\’mˆöŽq‚ƂȂ蓾‚é‚©H ˆê”ÊZ–¯ŒŸf‚É‚¨‚¯‚é‚W”NŠÔ‚É‚¨‚æ‚Ôc’fŒ¤‹†‚©‚ç\
  126. ‘æ30‰ñ@“ú–{‚ŒŒˆ³Šw‰ïŠwpW‰ïi2007”N10ŒŽ25?27“úF‹X–ì˜pj
    ŒF’JrˆêA‘«’B@ŽõA‰|–{”ü‰ÀA[…ˆŸŽqA‘å’Ë–ƒŽ÷A²“¡@WAŒÃ–Ø‹v”üŽqA“잊‘׋PA¡ò@•×FŒŒŸ÷ƒGƒ“ƒhƒZƒŠƒ“-1‚Í‚ŒŒˆ³i“W‚Ì—\’mˆöŽq‚ƂȂ肤‚é‚©H\ 7”NŠÔ‚Ì’ÇÕ‰uŠwƒRƒz[ƒgŒ¤‹†‚ÌŒ‹‰Ê‚æ‚è \
  127. ‘æ30‰ñ@“ú–{‚ŒŒˆ³Šw‰ïŠwpW‰ïi2007”N10ŒŽ25?27“úF‹X–ì˜pj
    ‚ŽR¬­Ab”ã‹vŽjAX@—²GA•‹{´ŽqA’r“c—–]AˆÀ‰ª@ˆíAŒÃ‰êˆò‹vAˆÀìG—YA¡ò@•×FƒVƒ“ƒoƒXƒ^ƒ`ƒ“‚ÍŒŒˆ³•Ï“®‚É‚æ‚éRhoA/Ras-ERKŒnŠˆ«‰»—}§‚ð‰î‚µ‚Ä‚ŒŒˆ³«S”ì‘呈«‚ð‰ü‘P‚·‚é[ƒXƒ^ƒ`ƒ“‚ÌV‚½‚ÈS•ÛŒìì—p-
  128. ‘æ30‰ñ@“ú–{‚ŒŒˆ³Šw‰ïŠwpW‰ïi2007”N10ŒŽ25?27“úF‹X–ì˜pj
    […ˆŸŽqA‘«’B@ŽõA‰|–{”ü‰ÀAŒF’JrˆêA‘å’Ë–ƒŽ÷A²“¡@WAŒÃ–Ø‹v”üŽqA“잊‘׋PA¡ò@•×FŒŒ´MCP-1‚ÍCardio-Renal Syndrome‚Ìkey factor‚ɂȂ蓾‚é‚©H@\ ˆê”ÊZ–¯‚ð‘ÎÛ‚Æ‚µ‚½‰¡’f“I‰uŠwŒ¤‹†‚æ‚è\
  129. ‘æ18‰ñ@“ú–{—Õ°ƒXƒ|[ƒcˆãŠw‰ïi2007”N11ŒŽ3?4“úF‘啪j
    Šâ‰i“Þ‰›A–L‘Œ÷ŽŸF‘åŠw¶‚̃‰ƒCƒtƒXƒ^ƒCƒ‹‚ÆŒ’N‚ɂ‚¢‚Ä
  130. ‘æ22‰ñ@“ú–{X”NŠúˆãŠw‰ïŠwpW‰ïi2007”N11ŒŽ17`18“úF“Œ‹žj
    ‰|–{”ü‰ÀA‘«’B@ŽõA[…ˆŸŽqAŒF’JrˆêA“잊‘׋PA¡ò@•×FŒŒ´DHEAS‚’l‚ÍA’j«‚Å‚Í’·Žõ‚Ì—\’mˆöŽq‚Å‚ ‚é@\27”NŠÔ‚̉uŠw“IŒŸ“¢\
  131. ‘æ279‰ñ@“ú–{“à‰ÈŠw‰ï‹ãB’n•û‰ïi2007”N11ŒŽ18“úF’·èj
    “ì@’mŽqA‹S’ˈê˜YAˆî–Ñ’qmA™@—Y‰îAŒ´Œû@„AŒÃ‘‘@•¶AŠâŒ³”üŽqA•½•û²‹GAb”ã‹vŽjA¡ò@•×F“Á”­«‰E–[”j—ô‚É”º‚¢Sƒ^ƒ“ƒ|ƒi[ƒf‚𗈂µ‚½ˆê—á
  132. ‘æ279‰ñ@“ú–{“à‰ÈŠw‰ï‹ãB’n•û‰ïi2007”N11ŒŽ18“úF’·èj
    ‘ºŽR‹±ŽqAˆî–Ñ’qmA‹g“c‹P‹vA‹S’ˈê˜YA™ —Y‰îA‰iŒ³NŽkAŒ “¡Œ’Ž÷A•Ÿ“c—TŽŸ˜YAb”ã‹vŽjA¡ò •×F•ÂÇ«”ì‘åŒ^S‹Øǂɑ΂·‚é DDD ƒy[ƒXƒ[ƒJŽ¡—ÂÉÛ‚µ‰EŽºƒŠ[ƒh‚Ì—¯’uˆÊ’u‚Æ dyssynchrony ‚Ì•]‰¿‚ðs‚Á‚½ˆê—á
  133. ‘æ15‰ñ@“ú–{ŒŒŠÇ¶•¨ˆãŠw‰ïŠwp‘å‰ïi2007”N11ŒŽ29?30“úF•Ÿ‰ªj
    Kajimoto H, Kai H, Imaizumi T, Archer SLFA crucial role of Rho/Rho-kinase pathway in constriction and closure of human and rabbit ductus arteriosus. Yasukawa H, Koga M, Yamamoto T, Kai H, Imaizumi T: Macrophage-specific deletion of suppressor of cytokine signaling-3 inhibits the development of atherosclerosis in mice.
  134. ‘æ103‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N12ŒŽ1“úF•Ê•{j
    –ƒ¶–¾Œ©A’†‘ºr”ŽAˆä㊰ŽqA´…’m•FAXˆä½ŽmA’‡‹gF°AX@—²GA–Ø‘ºD–MA‰¡ŽRW“ñAX@’´•vA²“¡^ŽiA—â–´“c_ŽiF–[ŽºÚ‡•”•p”—lŠŒ©‚ð”F‚ß‚½‚Æ–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[«•p”‚̈ê—á
  135. ‘æ103‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N12ŒŽ1“úF•Ê•{j
    ‹ž‹ÉKŽqAX“c”Ž•FA‘ê@Œ’AŒ´“c°mA‰Á“¡GŽiA’r“c‹v—YAŒÃ‰ê‹`‘¥F‚R‰ñ–Ú‚Ì”][ÇŒã‚É”­Œ©‚³‚ꂽ¶Žº“à“û“ªóüˆÛ’e«Žî‚̈ê—á
  136. ‘æ103‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N12ŒŽ1“úF•Ê•{j
    ãŠÔ@–²A“c’†M‰pA²“¡^ŽiA’‡‹gF°A™Œ´@[A´…’m•FAˆä㊰ŽqA’r“cŽŸ˜YAXˆä½ŽmA–ƒ¶–¾Œ©AX@—²GA–Ø‘ºD–MA‰¡ŽRW“ñAX@’´•vA’†‘ºr”ŽA—â–´“c_ŽiF•ÂÇ«”ì‘åŒ^S‹ØÇ—l‚ÌŒŒs“®‘Ô‚ð’悵‚½‚½‚±‚‚ÚS‹ØÇ‚Ì1—á
  137. ‘æ103‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N12ŒŽ1“úF•Ê•{j
    ´…’m•FA‰¡ŽRW“ñAˆä㊰ŽqA’r“cŽŸ˜YAXˆä½ŽmA’‡‹gF°A™Œ´@[A“c’†M‰pA–ƒ¶–¾Œ©AX@—²GA–Ø‘ºD–MAX@’´•vA²“¡^ŽiA’†‘ºr”ŽA—â–´“c_ŽiFŠ¥¹k‚ªŒ´ˆö‚Æl‚¦‚ç‚ê‚é‹}«S‹Ø[Ç‚ðŒJ‚è•Ô‚µ”­Ç‚µ‚½ˆê—á
  138. ‘æ103‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N12ŒŽ1“úF•Ê•{j
    ’m‰Ô‰prA‹S’ˈê˜YAˆî–Ñ’qmA™@—Y‰îAŒ´Œû@„A‘ºŽR‹±ŽqA•½•û²‹GAŒÃ‘‘@•¶A“ì@’mŽqAŠâŒ³”üŽqA’†‘ºŽÀ¶AV“c—ǘaA–ؗTŽiAˆä¯²’mŽqAb”ã‹vŽjA¡ò@•×F––’[”ì‘åÇ‚É‘å“®–¬•Ù•Â½•s‘S‚ð‡•¹‚µ‚½ˆêÇ—á
  139. ‘æ103‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N12ŒŽ1“úF•Ê•{j
    ’ËìŠG—AŒF’J‰p‘¾A“ˆ“cŽõ•¶A‘å’Ø@mA‰i“c—²MA‹T”ö@PA‘ê@Œ’FH2 Blocker“Š—^Œã‚ÉAŠ®‘S–[ŽºƒuƒƒbƒN‚ð’悵‚½‚½‚ßA‘ÌŠOŽ®ƒy[ƒXƒ[ƒJ[Ž{s‚µ‚½ˆê—á
  140. ‘æ103‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N12ŒŽ1“úF•Ê•{j
    ’ËìŠG—AŒF’J‰p‘¾A“ˆ“cŽõ•¶A‘å’Ø@mFá¿òAšq“f‚ðŽå‘i‚Æ‚µ‚½Žá”N«’Åœ“®–¬‰ð—£‚̈ê—á
  141. ‘æ103‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N12ŒŽ1“úF•Ê•{j
    ‰i“c—²MFH2 blocker“Š—^Œã‚ÉAŠ®‘S–[ŽºƒuƒƒbƒN‚ð’悵‚½‚½‚ßA‘ÌŠOŽ®ƒy[ƒXƒ[ƒJ[Ž{s‚µ‚½ˆê—á
  142. ‘æ103‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N12ŒŽ1“úF•Ê•{j
    V“c—ǘaA™@—Y‰îA–ؗTŽiAˆî–Ñ’qmA‹S’ˈê˜YAb”ã‹vŽjA¡ò@•×FÁ‰»ŠÇoŒŒ‚É‚æ‚é•nŒŒ‚Å—U”­‚³‚ꂽpostprandial syncope‚Ì1Ç—á
  143. ‘æ103‰ñ@“ú–{zŠÂŠíŠw‰ï‹ãB’n•û‰ïi2007”N12ŒŽ1“úF•Ê•{j
    Œ´Œû@„A’|“à’qGA‹g“c‹P‹vA‹S’ˈê˜YAˆî–Ñ’qmA™@—Y‰îA‰iŒ³NŽkAŒ “¡Œ’Ž÷A•Ÿ“c—TŽŸ˜YAb”ã‹vŽjA¡ò@•×F–òÜŽ¡—Ã’ïR«‚Ì‹N—§«’ጌˆ³‚ɑ΂µ‚ÄAV‚½‚ȃy[ƒVƒ“ƒOƒAƒ‹ƒSƒŠƒYƒ€‚ð—p‚¢‚½1—á

Œ°²

  1. •½¬19”N“x@’¹‹’É•—ŠwpÜ
    ‘«’B@ŽõFƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚ÆŒŒ´”AŽ_’l‚ÌŠÖ˜A @@@@@@@\@ˆê”ÊZ–¯ŒŸf‚É‚¨‚¯‚é‰uŠw“IŒŸ“¢@\
  2. •½¬19”N“x@ˆä‘º—Õ°Œ¤‹†§—ãÜ
    “cŒ´éLF“®–¬d‰»•a•Ï‚ÌŠˆ“®«Ž¡—ÃŒø‰Ê‚ɑ΂µ‚ÄFDG-PET‚ð—p‚¢‚½V‚µ‚¢”»’è–@‚ÌŠJ”­
  3. ‘æ3‰ñ@‚Ó‚­‚¨‚©u—Õ°ˆãŠwŒ¤‹†Üv
    “cŒ´éLF“®–¬d‰»•a•Ï‚ÌŠˆ“®«Ž¡—ÃŒø‰Ê‚ɑ΂µ‚ÄFDG-PET‚ð—p‚¢‚½V‚µ‚¢”»’è–@‚ÌŠJ”­
  4. ‘æ8‰ñ@ƒoƒCƒGƒ‹u—Õ°ŒŒŠÇ‹@”\vŒ¤‹†•¬@—DGÜ
    aŒûƒ~ƒmƒŠFƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚Í“®–¬d‰»‚̉ŠÇ‚ðŽä‹N‚·‚é[FDG-PET‚É‚æ‚錟“¢-

Œ¤‹†•¬‹à

  1. •½¬18”N“x?19”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@Šî”ÕŒ¤‹†(‚b)
    ‘«’B@ŽõFŽ‰–b‘gD—R—ˆƒTƒCƒgƒJƒCƒ“‚ÍAƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚ÆŠÖ˜A‚·‚é‚©Hi140–œj
  2. •½¬18”N“x?19”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@Šî”ÕŒ¤‹†(‚b)
    ã“cWéFSŒŒŠÇŒn‚É‚¨‚¯‚éLysyl Oxidaseƒtƒ@ƒ~ƒŠ[‚Ì–ðŠ„i170–œj
  3. •½¬18”N“x?19”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@Šî”ÕŒ¤‹†(‚b)
    –L‘Œ÷ŽŸFˆã—Ã]Ž–ŽÒ‚É‚¨‚¯‚éƒe[ƒ‰[ƒ[ƒhŒ^‚̃XƒgƒŒƒXƒ}ƒl[ƒWƒƒ“ƒg‚ÌŠJ”­‚ɂ‚¢‚Äi169–œj
  4. •½¬18”N“x?19”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@Šî”ÕŒ¤‹†(‚b)
    ¼‰ªG—mFPPARƒŠƒKƒ“ƒh‚ÌR‘½ŠjD’†‹…Šˆ«‚ð‰î‚µ‚½ŒŒŠÇ•ÛŒìì—p‚ÌŒŸ“¢i170–œj
  5. •½¬18”N“x?19”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@Šî”ÕŒ¤‹†(‚b)
    ˆÀìG—YFƒTƒCƒgƒJƒCƒ“ƒVƒOƒiƒ‹§ŒäˆöŽqSOCS‚ÌS•s‘S‚É‚¨‚¯‚é–ðŠ„‚Ì‰ð–¾‚ÆŽ¡—Âւ̉ž—pi360–œj
  6. •½¬18”N“x?19”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@Šî”ÕŒ¤‹†(‚b)
    ŽRŠÝ¹ˆêFŒŒŠÇV¶—}§ì—p‚ð‚à‚ÂF‘fã”ç—R—ˆˆöŽqƒyƒvƒ`ƒh‚Ìœ“÷ŽîŽ¡—Âւ̉ž—pi170–œj
  7. •½¬18”N“x?19”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@Šî”ÕŒ¤‹†(‚b)
    ‹g“c“TŽqF¶ŠˆKŠµ•a‚É‚¨‚¯‚éŽ_‰»ƒXƒgƒŒƒX‚©‚猩‚½‰^“®‚ÌŒø‰Êi140–œj
  8. •½¬18”N“x?•½¬20”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@Šî”ÕŒ¤‹†(C)
    aŒûƒ~ƒmƒŠF‡–°Žž–³ŒÄ‹zÇŒóŒQ‚ɇ•¹‚·‚é‚ŒŒˆ³ES•s‘SŠ³ŽÒ‚̈ÙíS“d}‚ÉŠÖ‚·‚é—Õ°Œ¤‹†i100–œj
  9. •½¬19”N“x?20”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@Šî”ÕŒ¤‹†(‚b)
    b”ã‹vŽjF«·‚©‚猩‚½‚ŒŒˆ³«S‚É‚¨‚¯‚é‘ŸŠíáŠQ‚Ì‹@˜‚̉ð–¾i190–œj
  10. •½¬18”N“x?19”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@ŽáŽèŒ¤‹†iBj
    ’†‘º˜a¶FF‘fã”ç—R—ˆˆöŽq‚É‚æ‚錌ŠÇ“à‹·ó—}§Œø‰Ê‚ÌŒŸ“¢i170–œj
  11. •½¬18”N“x?19”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@ŽáŽèŒ¤‹†iBj
    ²X–ØŒ’ˆê˜YFƒo[ƒWƒƒ[•a‚Ì‹•ŒŒŽˆ‚É”F‚ß‚ç‚ê‚錌ŠÇV¶áŠQ‚ÌŠî’²‚ƂȂ郃JƒjƒYƒ€i130–œj
  12. •½¬19”N“x?20”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@ŽáŽèŒ¤‹†iBj
    ¼ˆäFŒ›FF‘fã”ç—R—ˆˆöŽqiPEDFj‚̉Šú“œ”A•a«–Ô–ŒÇ‚É‚¨‚¯‚錌ŠÇ“§‰ß«‚Ì—}§i170–œj
  13. •½¬19”N“x`20”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@ŽáŽèŒ¤‹†iBj
    ‰|–{”ü‰ÀFŒŒ´NAGŠˆ«‚’l‚Í”]ESŒŒŠÇ•a‚Ì—L—Í‚È—\‘ªˆöŽq‚Å‚ ‚é‚©H\’·Šú‘OŒü‚«Œ¤‹†‚æ‚è\ (190–œ)
  14. •½¬19”N“x`20”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@ŽáŽèŒ¤‹†iBj
    ‘å’Ë–ƒŽ÷F“®–¬d‰»‚ÌŽw•W‚Æ‚µ‚Ä‚ÌŠÌ×–E‘BˆöŽq‚Ì—L—p«‚ÉŠÖ‚·‚é‰uŠw“IŒ¤‹† (170–œ)
  15. •½¬19”N“x`20”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@ŽáŽèŒ¤‹†iBj
    ²“¡@WFƒŒƒ€ƒiƒ“ƒgƒŠƒ|’`”’ƒRƒŒƒXƒeƒ[ƒ‹‚ÆŒz“®–¬d‰»i“W‚Ì‘OŒü‚«‰uŠwŒ¤‹† (200–œ)
  16. •½¬19”N“x`20”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@ŽáŽèŒ¤‹†iBj
    […ˆŸŽqFŒŒ´MCP-1‚̓ƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚ÆŠÖ˜A‚µ“®–¬d‰»«Ž¾Š³‚ÌŒ´ˆö‚ƂȂ蓾‚é‚©H (180–œ)
  17. •½¬19”N“x`20”N“x@•¶•”‰ÈŠwȉȊwŒ¤‹†”ï@ŽáŽèŒ¤‹†iBj
    ŒÃ–Ø‹v”üŽqF“àˆö«NO‡¬‘jŠQ•¨Ž¿ADMA‚ÍŒz“®–¬d‰»i“W‚Ì—\‘ªˆöŽq‚ƂȂ蓾‚é‚©H (240–œ)
  18. •½¬19”N“xi‘æ32‰ñj“ú–{Ž„—§ŠwZU‹»E‹¤ÏŽ–‹Æ’c@ŠwpŒ¤‹†U‹»Ž‘‹à
    ¡ò@•×FŒŒŠÇĶ‚É‚æ‚é––½“®–¬•ÂÇ«Ž¾Š³Ž¡—Ã-ŒŒŠÇV¶—}§ˆöŽq‚̧Œä‚É‚æ‚éV‚µ‚¢Ž¡—Ã-i180–œj
  19. •½¬19”N“x@Œú¶˜J“­È‰ÈŠwŒ¤‹†”ï•â•‹àu“«Ž¾Š³Ž•žŒ¤‹†Ž–‹Æv
    ¡ò@•×F“Á”­«S‹ØÇ‚ÉŠÖ‚·‚é’²¸Œ¤‹†”Çi140–œj
  20. •½¬19”N“x@–Ø‘º‹L”OzŠÂŠíà’cŽw’茤‹†•¬
    ¡ò@•×FŽ©ŒÈœ‘×–EˆÚA‚ð—p‚¢‚½AV‚µ‚¢‹•ŒŒ«––½_ŒoáŠQŽ¡—Ö@‚ÌŠJ”­i100–œj
  21. •½¬19”N“x@–Ø‘º‹L”OzŠÂŠíà’cŽw’茤‹†•¬
    ¡ò@•×FŒŒŠÇ“à”ç‘O‹ì×–EiEPCj“€Œ‹•Û‘¶–@‚ÌŠJ”­i100–œj
  22. •½¬19”N“x@΋´à’c•¬‹à
    b”ã‹vŽjF‰Â—nŒ^ƒCƒ“ƒ^[ƒtƒFƒƒ“ƒÁŽó—e‘Ì‚ð—p‚¢‚½V‚µ‚¢“®–¬d‰»Ž¡—Ẫgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`|Š®‘S¶‘Ì‹zŽûŒ^ƒR[ƒeƒBƒ“ƒOƒXƒeƒ“ƒg‚ÌŠJ”­|i1000–œj
  23. •½¬18”N“x?•½¬20”N“x ŽÔ—¼‹£‹ZŒö‰vŽ‘‹à‹L”Oà’c S‘Ÿ•a‚Ìæ‹ì“IŒ¤‹†•¬Ž–‹Æ
    b”ã‹vŽjFS•s‘S“‰»‚̃ƒJƒjƒYƒ€‰ð–¾‚ÆV‚µ‚¢Ž¡—Ö@‚ÌŠJ”­i500–œj
  24. •½¬19”N“x@Œö‰vM‘õƒ^ƒjƒ^Œ’N‘ÌdŠî‹àŒ¤‹†•¬
    ‘«’B@ŽõFŽ‰–b×–E—R—ˆ‚̃TƒCƒgƒJƒCƒ“‚ÍAƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚ÆŠÖ˜A‚·‚éHF”_‘º‚¨‚æ‚Ñ‹™‘º‚ł̈ê”ÊZ–¯‚ð‘ÎÛ‚Æ‚µ‚½‰uŠwŒ¤‹†i50–œj
  25. •½¬19”N“x@’É•—Œ¤‹†‰ïŠwpŒ¤‹†•¬
    ‘«’B@ŽõFƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚ÆŒŒ´”AŽ_’l‚ÌŠÖ˜A?ˆê”ÊZ–¯ŒŸf‚É‚¨‚¯‚é‰uŠw“IŒŸ“¢?(100–œ)
  26. ‘—§•a‰@‹@\Žå“±EBM„i‘å‹K–Í—Õ°Œ¤‹†
    —â–´“c _ŽiFŠ¥“®–¬Ž¾Š³Ž¡—Âɂ¨‚¯‚éƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“—Ö@‚̑Ó–«‚ɂ‚¢‚Ä‚ÌŒŸ“¢i400–œj
  27. ‘—§•a‰@‹@\Žå“±EBM„i‘å‹K–Í—Õ°Œ¤‹†
    —â–´“c_ŽiF‹}«S‹Ø[Ç‘S‘‹¤“¯Ž»ŠF’²¸‚É‚æ‚é—Õ°•]‰¿Žw•W‚Æ‚»‚Ì•]‰¿i100–œj
  28. ‘—§•a‰@‹@\Žå“±EBM„i‘å‹K–Í—Õ°Œ¤‹†
    ’†‘º r”ŽFS–[ד®‚É‚æ‚éSŒ´«”]Çð—\–h‚É‚¨‚¯‚éRŒŒð—Ö@‚ÌŽÀ‘Ô’²¸i36–œj
  29. •½¬19”N“x@•¶•”‰ÈŠwȎЉï˜AŒg„iŽ–‹Æ”ï
    ŽRŠÝ¹ˆêFF‘fã”ç—R—ˆˆöŽq‚Ì‚ª‚ñE“®–¬d‰»ÇŽ¡—Âւ̑Ήži4000–œj
  30. •½¬18”N“x?•½¬20”N“x@•¶•”‰ÈŠwÈ”­“WŒ^“sŽsƒGƒŠƒAŽYŠwŠ¯˜AŒg‘£iŽ–‹Æ
    ŽRŠÝ¹ˆêiŒ¤‹†•ª’SŽÒjFAGE‘jŠQ‹@”\«H•iŠJ”­ƒvƒƒWƒFƒNƒg
  31. ŒoÏŽY‹ÆÈ@’nˆæV¶ƒRƒ“ƒ\[ƒVƒAƒ€‘no„iˆÏ‘õŒ¤‹†”ï
    ŽRŠÝ¹ˆêF…—n«ƒGƒ‰ƒXƒ`ƒ“‚É‚æ‚éV‹K“®–¬d‰»—\–hŒ^‹@”\«H•i‚ÌŠJ”­i661,500‰~j
  32. ‘æ27‰ñi•½¬19”N“xj–Ø‘º‹L”OzŠÂŠíà’cŒ¤‹†•¬
    ˆÀìG—YFS•s‘S‚Ì”­Ç‚Æi“W‚É‚¨‚¯‚éƒTƒCƒgƒJƒCƒ“ƒVƒOƒiƒ‹§ŒäˆöŽq‚Ì–ðŠ„‚Ì‰ð–¾i100–œj
  33. •½¬19”N“x@“Æ—§s­–@l ˆã–òŠî”ÕŒ¤‹†ŠŽó‘õŒ¤‹†”ï
    ˆÀìG—YFJAKƒ`ƒƒVƒ“ƒLƒi[ƒ[§Œä‚É‚æ‚éƒAƒŒƒ‹ƒM[E‰ŠÇ«Ž¾Š³Ž¡—ÂÌVí—ªi500–œj
  34. ‘æ3‰ñ@‚Ó‚­‚¨‚©u—Õ°ˆãŠwŒ¤‹†Üv•¬
    “cŒ´éLF“®–¬d‰»•a•Ï‚ÌŠˆ“®«‚ÆŽ¡—ÃŒø‰Ê‚ɑ΂µ‚ÄFDG-PET‚ð—p‚¢‚½V‚µ‚¢”»’è–@‚ÌŠJ”­ i80–œj
  35. •½¬19”N“x@Ž“c‹L”OˆãŠw–òŠwU‹»à’c‘æ25‰ñŒ¤‹†•¬
    ²X–ØŒ’ˆê˜YFƒo[ƒWƒƒ[•a‚Ì‹•ŒŒŽˆ––½‚É”F‚ß‚ç‚ê‚錌ŠÇV¶áŠQ‚ÌŠî’²‚ƂȂ郃JƒjƒYƒ€i100–œj
  36. •½¬19”N“x@–«Ž¾Š³EƒŠƒnƒrƒŠƒeƒCƒVƒ‡ƒ“Œ¤‹†U‹»à’cŒ¤‹†•¬
    ‰|–{”ü‰ÀF˜V‰»‚ɉe‹¿‚ð‹y‚Ú‚·ˆöŽq‚̉ð–¾(100–œ)
  37. •½¬19”N“x@ç‘ã“cŒ’NŠJ”­Ž–‹Æ’c‘æ54‰ñˆãŠwŒ¤‹†•¬
    ŒF’JrˆêFƒGƒ“ƒhƒZƒŠƒ“-1‚Æ‚ŒŒˆ³Ç‹y‚Ñ“®–¬d‰»‚Ì”­Ç¥i“W‚ÌŠÖ—^‚ɂ‚¢‚Äi7”NŠÔ‚̉uŠw“I’ÇÕ’²¸j@(100–œ)
  38. ‘æ8‰ñ@ƒoƒCƒGƒ‹u—Õ°ŒŒŠÇ‹@”\vŒ¤‹†•¬
    aŒûƒ~ƒmƒŠFƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚Í“®–¬d‰»‚̉ŠÇ‚ðŽä‹N‚·‚é[FDG-PET‚É‚æ‚錟“¢-i50–œj
  39. •½¬19”N“x@‹{“cS‘Ÿ•aŒ¤‹†U‹»Šî‹à
    Š–{‰p”üF“àˆö«NO‡¬‘jŠQ•¨Ž¿(ADMA)‚ð‰î‚·‚é“®–¬ŠÇŽûk‚Ì•ªŽq‹@\Fˆâ“`Žq‰ü•Ïƒ}ƒEƒX‚ð—p‚¢‚½ŒŸ“¢i100–œj

“Á‹–